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Parkinson’s disease (PD) is the most common movement disorder and the second most common 
neurodegenerative disorder, with a prevalence of 1 to 2 individuals per 1000 at any age, 
increasing to 1% of the population above 60 years. The pathological hallmarks of PD are neuronal 
proteinaceous inclusions called Lewy bodies and neurites – rich in alpha-synuclein (αS) – and 
death of dopaminergic neurons in the pars compacta of the substantia nigra, which can only be 
detected in patients’ brains post mortem. Diagnosis is mainly based on the observation of the 
typical motor symptoms (tremor, rigidity, bradykinesia) caused by these molecular alterations. 
Although PD is considered a movement disorder, patients also suffer from a variety of non motor 
alterations, some of which (e.g. constipation) can occur even decades before the onset of the 
motor ones. Moreover, Lewy pathology has been found in patients not only in the central (CNS), 
but also in the peripheral and enteric nervous systems (ENS), suggesting a correlation between αS 
inclusions in these sites and non motor symptoms, and a possible spreading of the pathology from 
the periphery to the brain. This study is focused on gastrointestinal (GI) dysfunctions and 
specifically constipation, for which the relationship with PD development is still poorly 
understood.  
For this research we used a transgenic (Tg) mouse model over-expressing human A53T αS under 
the control of the murine PrP promoter (line G2-3), one of the first genetic model developed to 
study α-synucleinopathies (which include PD). These mice develop neurological abnormalities 
after 9 months of age that manifest with motor symptoms which become progressively more 
severe culminating into a fatal paralysis within 14-21 days. Diseased mice show an accumulation 
of intracellular, phosphorylated and ubiquitinated αS inclusions, neuroinflammation and neuronal 
degeneration in the CNS. For the purpose of this study, sick αS Tg mice at 12-14 months, 
presymptomatic mice at 1, 2, 3, 6, 9 and 12 (if still healthy) months, and age-matched nTg 
littermate controls were used. Presymptomatic αS Tg mice displayed a drastic delay in GI transit 
time of almost 2 hours from 3 months old that increased with age, reaching more than 3 hours 
delay at 6 months. Such delay was associated with abnormal formation of stools for αS Tgs, that 
resulted in less abundant but longer pellet excreted, although normal for dry and wet weight. After 
that we recorded the contractile activity from longitudinal and circular muscle preparations of 
colon and ileum, to verify the intestinal function. In line with our previous observations, 
electrically evoked contractions of the colon, but not of the ileum, showed a reduced response in 
both muscle layers in αS Tg mice already at 3 months of age, mainly due to an impaired 
cholinergic transmission of the ENS. Furthermore, molecular analyses were carried out to check 
on αS enteric distribution. Interestingly, insoluble and aggregated αS was found in enteric neurons 
in both myenteric and submucosal plexi only in the colon and not in the small intestine of 3 
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months old Tg mice, and exacerbated with age, mimicking the increase in transit delay and 
contraction deficits showed in behavioral and electrical recording experiments. 
Following this GI characterization of PrP A53T αS Tg mice, we designed a disease modifying 
therapy to be carried out with an antisense oligonucleotide (ASO) against αS, in presymptomatic 
animals. After an in vitro evaluation, the selected ASO was administred to 10 weeks old Tg mice 
for 7 days, through osmotic pumps or rectal administration. Very surprisingly, Tg mice which 
received the ASO displayed a significant reduction in their GI transit time compared to the values 
before starting the treatment and to the PBS control group, for both administration routes. 
Together with the improvement in constipation, ASO treatment induced a reduction, although not 
significant, of the total level of αS in the distal colon for both delivery methods. 
This research demonstrates for the first time that the PrP human A53T αS Tg mice line G2-3 is a 
unique model to investigate GI dysfunction in prodromal PD, thanks to the net spatio-temporal 
separation of αS-driven pathologies in the ENS and in the CNS. Moreover, the promising results 
obtained in this model by using an ASO peripherally support the correlation between GI behavior 
and αS levels and the hypothesis that lowering the total level of αS can be a successful disease 






Alpha-synuclein (αS)  
Alpha-synuclein human gene (SNCA) 
Antisense oligonucleotide (ASO) 
Blood brain barrier (BBB) 
Blood nerve barrier (BNB) 
Central nervous system (CNS) 
Distal colon (D) 
Dopamine (DA) 
Dorsal motor nucleus of the vagus nerve 
(dmX) 
Electrical stimulus (ES) 
Endoplasmic reticulum (ER) 
Enteric nervous system (ENS) 
Full length (FL) 
Gastrointestinal (GI) 
High molecular weight (HMW) 
Lewy bodies (LBs) 
Lewy neurites (LNs) 
 
Non transgenic (nTg) 
Non amyloid β-component (NAC) 
Over night (o/n) 
Parkinson’s disease (PD) 
Proximal colon (P) 
Peripheral nervous system (PNS) 
Paraformaldehyde (PFA) 
Phosphate-buffered saline (PBS) 
Prion protein (PrP) 
Room temperature (RT) 
Standard error mean (SEM) 
Substantia nigra (SN) 
Substantia nigra pars compacta (SNpc) 
Substantia nigra pars reticulata (SNpr) 
Small ubiquitin-related modifier (SUMO) 
Tris-buffered saline (TBS) 
Transgenic (Tg) 










Parkinson’s disease (PD) is the most common movement disorder and the second most common 
neurodegenerative disorder, after Alzheimer’s disease. The prevalence of PD increases with 
aging: it counts 1 to 2 affected individuals per 1000 at any age (Von Campenhausen et al., 2005), 
1% of the population above 60 years (de Lau and Breteler, 2006) and 4% above 85 years (de Rijk 
et al., 1995). The age of onset is usually between 65 to 70 years, and only for a rare recessive 
form it occurs before the age of 40, in less than 5% of the cases (Tysnes and Storstein, 2017). PD 
is an irreversible and slowly progressive neurodegenerative movement disorder that impairs 
movement control. Together with multiple system atrophy, dementia with Lewy bodies (Peelaerts 
et al., 2018) and pure autonomic failure (Kaufmann et al., 2017), PD belongs to a group of 
diseases named α-synucleinopathies, because of the abnormal accumulation of intracellular 
proteinaceous inclusions mostly made of aggregated alpha-synuclein (αS). Specifically, the 
pathological hallmarks of PD are the loss of dopaminergic neurons in the substantia nigra pars 
compacta (SNpc) and the presence of αS positive intraneuronal inclusions called Lewy bodies 
(LBs) or Lewy neurites (LNs), depending on whether they are located in the soma or in the 
neurites, respectively (Goedert et al., 2013). LBs and LNs were discovered by Freiderich Lewy in 
1912, but only after almost a century it has been described that they are mainly composed by 
fibrillar aggregates of post-translationally modified αS and ubiquitin (Spillantini et al., 1997), 
together with a large number of other constituents, such as tau, parkin and neurofilaments (Arima, 
1999; Schlossmacher et al., 2002; Shults, 2006). 
 
 
Fig.1.1 The pathological hallmarks of clinical PD. A) 
Transverse hemisection of the midbrain of a control and a 
patient with clinical PD, showing the marked reduction in the 
black pigment within the substantia nigra region. B, C) 
Haematoxylin and eosin stained sections showing at higher 
magnification the pigmented neurons of the substantia nigra in 
a control (B) and a PD patient (C). D, E) Intracytoplasmic LBs 
in remaining pigmented neuron of the substantia nigra of a 
subject with clinical PD, showing the eosinophilic core and 
paler halo in haematoxylin and eosin staining (D) and the dark 
aggregation of αS using immunoperoxidase with cresyl violet 
counterstaining (E) (Obeso et al., 2017). 
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Etiology of PD 
 
As for many neurodegenerative diseases, the etiology of PD is still unknown for most identified 
cases. PD is a multifactorial disorder, for which several factors (genetics, aging, environment) are 
thought to play a role in causing the pathology. Concerning the environmental aspect, it has been 
shown that exposure to certain pesticides (e.g. rotenone, paraquat, maneb), heavy metals (e.g. Fe, 
Mn, Cu), toxins such as 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) can lead to PD 
(Polito et al., 2016). Tobacco, alcohol and coffee consumption are examples of environmental 
factors negatively correlated with the risk of developing PD (Kalia and Lang, 2015). 
As for the genetics, two main forms of PD can be distinguished, the hereditary or familial form, 
which accounts for about 5-10% of total cases, and the idiopathic or sporadic form for all the 
others (Lill, 2016). Several gene loci have been linked to the familial form of PD, and first degree 
family members of affected patients have a 2- to 3-fold increased risk to develop the disease 
compared to control subjects in the general population (Sveinbjornsdottir et al., 2000; Savica et 
al., 2016). To date, the mutations present in the αS gene (SNCA) and the LRRK2 gene account 
for the majority of genetic PD pedigree identified and are responsible for the autosomal-dominant 
transmission of the disease. In most of these cases, the symptomatology and pathogenesis do not 
differ from the sporadic form of PD. Autosomal-recessive forms of PD have also been described. 
The most frequent is associated with mutations in the Parkin gene. The transmission of this form 
is more rare and differs from the other cases (both genetic or sporadic), including an early onset 
(before 30-40 years of age). It is interesting to notice that, even in cases of sporadic PD, several 
PARK-designated polymorphisms (SNCA, UCHL1, LRRK2, PARK 16, GAK) and a few others 
(MAPT, GBA, NAT2, INOS2A, GAK, HLA-DRA, APOE) have been linked to a higher risk of 
developing the disease, because of a genetic predisposition. Specifically, the polymorphic length 
and single-nucleotide polymorphism (SNP) variations in the SNCA gene are known to be the 
most significant risk factors, followed by the occurrence of the G2385R and R1628P missense 
SNPs in the LRRK2 gene. In addition to SNCA and LRRK2, which can be both associated to the 
monogenic disease and a major risk factor, heterozygous β-glucocerebrosidase mutations and tau 
variants are examples of PD-associated risk factor (Klein and and Westernberger, 2012; Rana et 




PARK locus Gene State Inheritance Function 
PARK1/4 SNCA Confirmed AD 
Protein aggregation; prion-like transmission; 
synaptic function 
PARK2 PARKIN Confirmed AR 
Mitochondrial maintenance; mitophagy; 
ubiquitin-proteasome 
PARK3 Unknown Putative AD Unknown 
PARK5 UCH-L1 Putative AD Ubiquitin hydrolase 
PARK6 PINK1 Confirmed AR Mitochondrial function; mitophagy 
PARK7 DJ-1 Confirmed AR Mitochondrial function; cell stress response 
PARK8 LRRK2 Confirmed AD 
Protein and membrane trafficking; neurite 
structure; lysosomal autophagy; synaptic 
function 
PARK9 ATP13A2 Confirmed AR 
Lysosomal autophagy; mitochondrial 
function 
PARK10 Unknown Confirmed Risk factor Unknown 
PARK11 GIGYF2 Putative AD 
Tyrosine kinase receptor signalling; insulin-
like growth factor pathway 
PARK12 Unknown Confirmed Risk factor Unknown 
PARK13 HTRA2 Putative AD Mitochondrial function 
PARK14 PLA2G6 Confirmed AR Mitochondrial function 
PARK15 FBX07 Confirmed AR 
Mitochondrial maintenance; mitophagy; 
ubiquitin-proteasome 
PARK16 RAB7L1 Confirmed Risk factor 
Protein and membrane trafficking; 
lysosomal autophagy 
PARK17 VPS35 Confirmed AD Lysosomal autophagy; endocytosis 
PARK18 EIF4G1 Putative AD Protein translation 
PARK19 DNAJC6 Confirmed AR Synaptic function; endocytosis 
PARK20 SYNJ1 Confirmed AR Synaptic function; endocytosis 
                                               
Tab.1.2 PARK loci and identified genes linked to familial PD. The five genes underlined in bold account 
for the monogenic form of the disease. The most characterized point mutations in the SNCA gene are 
A53T, A30P and E46K. Heterozygous mutations in the LRRK2 gene are responsible for autosomal-
dominant PD (Zimprich et al., 2004). Heterozygous loss-of-function mutations in the PARK2 gene are 
responsible for the autosomal-recessive form, also referred to as juvenile PD because of its early onset 





Motor circuits in PD 
 
The loss of SNpc neurons in PD patients gradually leads to a severe striatal dopamine (DA) 
deficiency, which is responsible for the major motor symptoms. For this reason, the main 
treatment still in use is L-DOPA, a DA precursor which replaces the striatal DA and thus 
improves motor dysfunction. In healthy subjects, motor cortical areas are involved in the planning 
and execution of movements. In order to perform smooth and fine motor tasks, motor cortical 
areas have to communicate with deep brain circuits, among which a pivotal role is played by a 
group of nuclei called basal ganglia (Mink, 1996). The basal ganglia count several interconnected 
subcortical nuclei: the striatum (caudate and putamen), the globus pallidus externus, the globus 
pallidus internus, the substantia nigra (SN), and the subthalamic nucleus. This network 
differentially connects with motor cortical areas (Obeso et al., 2000). In particular, there are two 
loops, the direct and indirect pathways, which originate from two different populations of striatal 
projecting neurons and project to different nuclei. These pathways have opposite effects on 
movement, meaning that the direct pathway promotes it, whilst the indirect one inhibits it (Kravitz 
et al., 2013). The crucial role of the nigrostriatal circuit is to exert the dual effect of exciting the 
direct pathway and inhibiting the indirect one. The SN is made of two distinct structures, the 
SNpc and the SN pars reticulata (SNpr). The neurons of the SNpc contain neuromelanin and use 
DA as neurotransmitter. The main recipients of nigral projections are the striatum, the 
subthalamic nucleus and the globus pallidus. In PD patients, the loss of DA neurons in the SNpc 
affects only the nigrostriatal circuit and leads to a severe DA denervation of the striatum (Blandini 
et al., 2000). The loss of nigrostriatal DA neurons leads to bradykinesia or akinesia in PD patiens, 
since the indirect pathway inhibition of motor cortex overtakes the direct pathway excitation of 













Fig.1.3 Schematic diagram illustrating the changes occurring in the basal ganglia functional 
organization in PD, compared to normal condition. Relative thickness of arrows indicate the degrees 
of activation of the transmitter pathways. Medial globus pallidus, MGP; lateral globus pallidus, LGP; 
substantia nigra pars compacta, SNc; substantia pars reticulate, SNr; subthalamic nucleus, STN 
(Blandini et al., 2000). 
 
Besides voluntary movements, DA can control higher brain functions such as motivated behaviors 
and emotional states. While changes in these latter circuits could partially explain certain non 
motor symptoms in PD, it has been shown recently how neuronal loss is not limited to DA 
neurons in the SNpc, but it also affects other neuronal populations such as serotoninergic neurons 
in the raphe and cholinergic neurons in the basal forebrain (Braak et al., 2003a; Bohnen and 
Albin, 2011). In fact, loss of cholinergic neurons in specific areas has been related to non motor 
symptoms such as memory loss and cognitive dysfunction, serotoninergic to depression and mood 
disturbances, and adrenergic to attention dysfunction (Pillon et al., 1989). 
 
Motor and non motor symptoms 
 
PD diagnosis is currently made upon the presence of typical motor symptoms (bradykinesia, 
rigidity and tremor) caused by death of DA neurons in SNpc. Bradykinesia is the slowness of 
initiation of voluntary movements with a progressive reduction of speed and amplitude, rigidity is 
defined as stiffness and increased tone of muscles, and PD tremor is specifically a 4- to 6-Hz rest 
tremor. All these features usually manifest unilaterally or at least asymmetrically. Recently, 
postural instability has been removed from initial diagnostic criteria, since it usually appears in 
patients during the late phases of the disease (Berardelli et al., 2013). As previously mentioned, 
the symptomatic therapy used for PD patients to date (L-DOPA) focuses on DA replacement 
strategies. Unfortunately, the progression of the disease and increased doses of L-DOPA lead to 
the appereance of motor complications, characterized by fluctuations between “on” and “off” 
periods (respectively presence and absence of motor symptoms control effect) and dyskinesias, 
defined as involuntary choreiform or dystonic movements. These complications are often worse 
for patients compared to the original symptoms, and can be accompanied by non motor 
complications such as psychosis. It is important to underline that already from the first 
observations by James Parkinson (1755 –1824) more than two centuries ago and by Jean-Martin 
Charcot (1825-1893) right after him, clinical features of PD patients have always revealed a very 
complex setting, with a plethora of non motor symptoms which unfortunately did not get the 
deserving attention in the following decades.  
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Fig.1.4 Drawing by Jean-Martin Charcot (1887) 
depicting the typical flexion posture of a PD patient. 
The French neurologist gave a great contribution to the 
clinical studies on PD, expanding and refining the early 
descriptions made by James Parkinson, about half a 
century before. (Goldman and Goetz, 2007). 
 
 
The first contemporary account on non motor symptoms occured in fact after the introduction of 
L-DOPA in the 1960s, when clinicians and scientists started to report that the drug could improve 
several non motor dysfunctions such as sialorrhea, mood disturbances, constipation and dysuria 
(Barbeau, 1969; Yahr et al., 1969). Non motor symptoms were finally taken into account, but it 
took till the 21
st
 century to really appreciate and measure their impact on PD (Martinez-Martin et 
al., 2011; Erro et al., 2013; Špica et al., 2013; Kalia and Lang, 2015). Overall, the variety of 
symptoms experienced by PD patients which affects both the central nervous system (CNS) and 
the peripheral nervous system (PNS) has obviously a deep impact on their quality of life, but 
probably the most important aspect of non motor dysfunctions is that not only they occur across 
all motor stages of PD, but some of them are present very early during its prodromal phase. In 
particular, GI and olfactory dysfunctions (partial or total loss of smell, named hyposmia or 
anosmia respectively) can arise even decades before the onset of motor abnormalities (Fasano et 
al., 2015; Schapira et al., 2017), and this is why their analysis can be potentially useful for early 
diagnosis and therapeutic intervention. 
 
 
Fig.1.5 Time course progression of PD and related symptoms. Diagnosis of PD (at time 0) is made upon 
the onset of motor symptoms (tremor, rigidity, bradykinesia), preceded by a prodromal phase of 20 years or 
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more, characterised by specific non motor dysfunctions. Additional non motor features arise after diagnosis 
during the progression of the pathology, with a strong impact on the quality of life of patients. Axial motor 
symptoms, such as postural instability with frequent falls and freezing of gait, are no longer considered for 
diagnosis, since they tend to appear during the advanced stages. Long-term complications of L-DOPA 
therapy (fluctuations, dyskinesia, psychosis) contribute to disability of patients. EDS, excessive daytime 
sleepiness; MCI, mild cognitive impairment; RBD, REM sleep behaviour disorder (Kalia and Lang, 2015). 
 
By affecting up to 80% of PD patients, constipation represents the most frequent GI dysfunction 
in PD (Cersosimo et al., 2013) and even Parkinson in his famous essay says “the bowels, which 
had been all along torpid, now in most cases, demand stimulating medicines of very considerable 
power” referring to constipation in patients suffering of the “shaking palsy”. We now know that 
patients with a previous diagnosis of constipation have an increased risk of developing PD (Stirpe 
et al., 2016), e.g. less than one bowel movement per day is linked to a 2.7-fold increase in risk 
(Abbott et al., 2001). A more accurate definition of constipation reports infrequent bowel 
movements, impairment of propulsive colonic motility, prolonged colonic transit time, reduced 
rectal contractions and abnormalities in motor activity of the anal sphincter of the patients 
(Andrews and Storr, 2011). However, to date we still know very little about the relationship 
between bowel dysfunctions and development of PD, mostly because there is a lack of animal 





αS, β-synuclein and γ-synuclein are the three proteins which compose the family of synucleins, 
discovered by Maroteaux in 1988 (Maroteaux et al., 1988). At first, αS was found to be present in 
the nucleus (the name etymologically means “with the nucleus”) and in the presynaptic terminals 
of neurons. In 1997, this protein was linked to the autosomal-dominant form of PD, after the 
missense mutation A53T (a threonine substitution to an alanine at position 53) in the SNCA gene 
was found in a family pedigree with early onset PD (Polymeropoulos, 1997). Remarkably, the 
very same year another study showed that αS is the major constituent of LBs and LNs (Spillantini 
et al., 1997). These two independent findings gave for the first time a strong proof that the SNCA 
gene, both with mutated and wild-type isoforms, is associated to genetic and sporadic PD and 
other α-synucleinopathies. 
The gene encoding for human αS contains 10 exons and is located in the long arm of chromosome 
4 at position 22.1. Besides the A53T mutation, which to date is the most recurrent and better 
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characterized (Polymeropoulos, 1997), several other missense mutations in the SNCA gene, 
associated with familial PD and dementia with LBs, have been mapped in the following years, 
e.g. A30P (Krüger et al., 1998), E46K (Zarranz et al., 2004), H50Q (Appel-Cresswell et al., 2013; 
Proukakis et al., 2013), G51D (Lesage et al., 2013a) and A53E (Pasanen et al., 2014). In addition, 
duplication or triplication of the SNCA gene have been related to genetic PD, proving that the 
pathology can also be caused by only increasing the amount of the wild-type protein (Singleton et 
al., 2003; Ibáñez et al., 2004). All missense mutations and amplifications of the SNCA gene were 
associated with a dominant inheritance and an early onset of the disease compared to the sporadic 
forms. Due to the fact that overexpressing wild-type or mutated αS leads to neurodegeneration in 
various animal models (Feany and Bender, 2000; Masliah, 2000; Lakso et al., 2003), whereas 
ablating αS has little or no effect in mice (Abeliovich et al., 2000), αS toxicity has been linked to 
a gain-of-function mechanism, in which an altered version of the protein ultimately causes 
neuronal damage. 
 
Physiology of αS 
 
αS is an acidic protein made of 140 amino acids, with a molecular weight of about 14 kDa, 
mainly expressed in neurons and possibly oligodendrocytes (in very low amount and still under 
debate) of the CNS (Asi et al., 2014), but also in the PNS, in circulating blood cells and in 
hematopoietic cells of the bone marrow, under physiological conditions (Nakai et al., 2007; 
Gardai et al., 2013). 
The structure of the protein can be divided in three regions:  
 
1. the N-terminal domain (residues 1-60) is amphipathic and interacts with 
phospholipids present in membranes and micelles, it also contains the sites for 
missense point mutations responsible for monogenic familial PD; 
2. the non amyloid β-component (NAC) (residues 61-95) is hydrophobic and plays an 
important role in self-aggregation (El-Agnaf et al., 1998); the name derives from the 
fact that this fragment of the protein was identified in senile plaques of AD patients 
although not as abuntant as the Aβ peptide;  
3. the C-terminal domain (96-140) is acidic because of a higher proportion of charged 
residues and represents the main site of post-translational modifications, truncation 
(Li et al., 2005) and interaction with modulators of the aggregation e.g. metal cations 




The whole protein accounts seven imperfect 11-residues repeats with a conserved hexameric 
sequence (KTKEGV) predicted to form an amphipathic α-helix: four in the N-terminal region and 
three in the NAC region (George et al., 1995). This domain seems to serve also as a hidden 
mitochondrial targeting sequence, potentially linking αS to mitochondrial dysfunctions (Devi et 
al., 2008). 
 
Fig.1.6 αS protein in humans. αS protein is made of 140 amino acids, in which several point mutations 
(highlighted in red) have been associated with genetic forms of PD (Polymeropoulos et al., 1997; Krüger et 
al., 1998; Lesage et al., 2013b; Appel-Cresswell et al., 2013; Zarranz et al., 2004). The protein can be 
divided into three regions: a N-terminal domain (light blue), deputed to membrane binding; the NAC 
domain (yellow), responsible for fibril formation (El-Agnaf et al., 1998) and a C-terminal domain (blue) 
relevant for the interaction with other proteins. There are seven imperfect repeats made of 11 residues each 
(depicted in purple), a highly conserved motif predicted to form an α-helix structure (George et al., 1995), 
which is located between the N-terminal region and the NAC core. It is interesting to notice that the 
missense point mutations discovered up to date are all located within the N-terminal region, suggesting that 
membrane binding may play an important role in the process of αS aggregation (Miraglia et al., 2018). 
 
αS is intrinsically disordered, with an unfolded native conformation, soluble in the cytosol under 
physiological conditions (Weinreb et al., 1996). In fact, whilst αS from mouse brain purified by 
gel-filtration elutes as a single peak with a 63 kDa molecular mass, which means close to a folded 
tetramer, mass spectrometry and circular dichroism analysis detect a monomeric conformation of 
17 kDa (slightly larger than expected, probably because of an in vivo N-terminal acetylation) 
(Burré et al., 2013). In line with these recent data, NMR studies show that acetylated αS, which is 
the main form in physiological conditions, is in fact a disordered monomer that adopts a more 
compact conformation in solution which prevents further interactions of the NAC domain within 
the cytosol (Theillet et al., 2016). The unfolded and disordered monomeric conformation of αS 
was confirmed in rat and human brain and erythrocytes isolated under denaturing and non 
denaturing conditions, and in bacteria expressing αS, whilst no oligomer species were present 
(Fauvet et al., 2012) in physiological conditions. On the opposite, another study has shown that 
αS extracted in non denaturating conditions and upon cross-linking in living cells (e.g. human 
erythrocytes, cell lines and brain tissue), is mainly a metastable homo-tetramer with a molecular 
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weight of 58 kDa. The tetramer is in a dynamic equilibrium with the unfolded monomer, which is 
more prone to aggregation (Bartels et al., 2011). Another independent study suggested a homo-
tetramer structure for αS under physiological conditions (Wang et al., 2011) and demonstrated 
that its subunits are held together by hydrophobic interactions. Following these results, it was 
suggested that αS tetramer and monomer co-exist in physiological conditions and any 
perturbation of this state due to higher levels of the monomer is linked to αS aggregation and 
pathology. Consistently with this view, some missense mutations were shown to reduce the 
tetramer : monomer ratio and to trigger neurotoxicity (Dettmer et al., 2015a, 2015b). Recently, αS 
was found to bind synaptic vesicles in vivo not as a monomer but in a folded α-helical multimer 
conformation, larger than an octamer (Burré et al., 2014). This structure has a specific orientation 
which only happens when the vesicles are docked at the cell membrane.  
αS is expressed by several neuronal populations within CNS and PNS, accounting for as much as 
1% of total proteins in soluble cytosolic brain fractions, and it has been often shown that it plays a 
role in general neuronal function. Nevertheless, its precise function still remains elusive, just like 
for many of the misfolded proteins found in other neurodegenerative diseases. Although αS does 
not possess a transmembrane domain or a lipid anchor, it interacts stably with synthetic 
phospholipidic vesicles containing negatively charged head groups, various phospholipid 
membranes, fatty acids, micelles and with biological membranes (Fortin, 2004). Interestingly, 
monomeric αS bound to membranes can efficiently prevent lipid oxidation, suggesting another 
physiological role of the protein (Zhu et al., 2006). Fractionation of healthy brain extracts 
revealed a portion of αS in association with synaptic vesicles, explained by its preference for 
membrane with high curvature (Jensen et al., 2011), although as previously said the vast majority 
of αS behaves as soluble protein (Fortin, 2004). αS is one of the last proteins to localize at 
presynaptic terminals during development since it is not essential for their formation (Withers et 
al., 1997). The protein is able to bind membrane vesicles on the cytosolic side but also to reside in 
the vesicle lumen and be secreted through exocytosis (Lee, 2005). This close association with 
vesicular structures has led to the hypothesis that αS may regulate vesicular release and/or 
turnover and other synaptic functions in the CNS. In line with this view, a research group proved 
that αS knock-out mice exhibit exaggerated levels of DA release following stimulation, 
suggesting a modulatory role for DA neurotransmission (Abeliovich et al., 2000). Another study 
showed that αS regulates catecholamines release from the synaptic vesicles and its over-
expression inhibits a vesicle priming step that occurs after secretory vesicle trafficking to docking 
sites but before calcium-dependent vesicle membrane fusion (Larsen et al., 2006). More recently, 
several studies clarified that αS is a chaperone of the SNARE complex (Burré et al., 2010; 
Nemani et al., 2010; Diao et al., 2013; Wang et al., 2014). This complex is made of vesicular 
SNARE proteins (v-SNARE) and target membrane SNARE proteins (t-SNARE), which allow 
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vesicular fusion to cell membrane after assembly. The assembly process is potentiated by αS 













Fig.1.7 Functional properties of αS. A, B) Wide field and magnification of cultured cortical murine 
neurons, showing dendrites (MAP2 staining in red) and αS-positive presynaptic densities (green), indicating 
that αS is located in the presynaptic terminals. C) Scheming of αS roles at the presynaptic terminal in the 
regulation of vesicle trafficking and vesicle refilling (blue), and its interaction with t-SNARE or v-SNARE 
proteins and neurotransmitter release. αS accumulation induces an impairment of neurotransmitter release, 
vesicle recycling and trafficking between synaptic buttons and influence t-SNARE complex assembly 
stability (red), whilst its depletion induces an impairment of vesicle trafficking between the reserve pool 
and the ready releasable pool and a deficiency in vesicle refilling and neurotransmitter uptake (Lashuel et 
al., 2013). 
 
Furthermore, αS has been associated to intracellular protein trafficking e.g. vesicle transport from 
the endoplasmic reticulum (ER) to Golgi (Cooper et al., 2006; Gitler et al., 2008; Thayanidhi et 
al., 2010; Oaks et al., 2013) and from Golgi to endosomes/lysosomes (Chung et al., 2013; 
Volpicelli-Daley et al., 2014; Breda et al., 2015; Mazzulli et al., 2016). In line with this, αS was 
also identified as an inhibitor of phospholipase D2, an enzyme implicated in membrane 
trafficking and specifically exocytosis (Bendor et al., 2014). Finally, it has been recently reported 
that αS acts as a molecular dynamase and directly binds to microtubules, thus promoting their 




Pathology of αS 
 
Apart from the debate on αS physiological state, the necessary step for the formation of LBs and 
LNs or in general insoluble αS inclusions is the transition of the protein to an aggregated β-sheet 
conformation. In their amyloid state, αS monomers form an antiparallel in-register β-sandwich 
fold, which in turn stacks into a parallel arrangement forming the so called protofilaments (Vilar 
et al., 2008; Tuttle et al., 2016). Protofilaments further assemble into mature fibrils. The process 
of aggregation is nucleation-dependent and occurs in a sequential series of steps, inside of which 
detours can still happen. Based on in vitro experiments we are now able to define a precise time 
course for this fibrillation process: at first there is a lag phase, in which the monomers convert 
into an oligomer-type of conformation (nucleation), then there is a growth phase and finally a 
steady state which terminates with the accumulation of -sheet amyloid fibrils (Cremades et al., 
2012). Oligomers are low molecular weight aggregates, which can be soluble or insoluble, and do 
not have a fibrillary organization. After the formation of the seeds, αS fibrils grow by the addition 
of monomers more likely than oligomers (Buell et al., 2014). To date, two different aggregate 
polymorphs, called fibrils and ribbons, have been described in vitro after using different 
aggregation protocols. Fibrils and ribbons differ biochemically and for seeding properties, and 
there may be more of these polymorphs still to discover (Bousset et al., 2013; Guo et al., 2013).  
The role of αS oligomers and aggregates in PD has been largely studied and is still under debate. 
The fact that fibrillar αS is found in LBs strongly suggests an involvement of the aggregation 
process in the pathogenesis of α-synucleinopathies, nevertheless it has also been suggested that αS 
aggregation might merely represent a by-product of metabolism or even act as a neuroprotective 
player. In support of this hypothesis is the observation that LBs formation does not always 
correlate with neurological symptoms (Braak et al., 2003a), or that in some forms of genetic PD 
αS aggregation is not present (Schneider and Alcalay, 2017). On the other hand, a recent study 
demonstrated that all the αS types of aggregates (fibrils and ribbons) generated in vitro are 
potentially toxic and can trigger different histopathological phenotypes, supporting the concept of 
heterogeneity among α-synucleinopathies (Peelaerts et al., 2015). For what concerns αS 
oligomers, several forms have been described in vitro, with different sizes and morphologies, 
including spherical, annular and tubular structures (Lashuel et al., 2002). Another difference is 
that some are amorphous and non fibrillar assemblies, while others are described as on-
fibrillization pathway. The aggregation process can be affected by many factors, e.g. protein 
concentration, specific physico-chemical conditions, the presence of certain ligands (including 
DA) and cross-linking (Buell et al., 2014). Therefore it is still unclear whether the heterogeneity 
among oligomers has a real physiological relevance or it is due to the protocol used for 
aggregation and working conditions. Recent studies helped unravel some of these issues, by 
directly following the oligomerization reaction using single molecule fluorescence techniques. 
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What they independently demonstrated is that the oligomers pool mainly consists of two different 
species, type A and type B, which assemble in the early stages of aggregation (Chen et al., 2015; 
Cremades et al., 2012). These two types of oligomers showed different chemical, structural and 
toxic properties. Type B oligomers are more resistant to protease K digestion than type A and 
need a longer lag time for formation, arising the hypothesis that they could derive from the 
conversion and rearrangement of type A oligomers. Moreover, type B oligomers present a higher 
amount of β-sheets that are instead negligible in type A (Fusco et al., 2017). In vivo experiments 
showed that type A oligomers could enter the cell and trigger aggregation in it, indirectly causing 
cell death type, whereas type B oligomers induced death of neuronal cells through the disruption 
of cellular ion homeostasis and production of reactive oxygen species, which separately caused 
mitochondrial dysfunction (Danzer et al., 2007; Fusco et al., 2017). Interestingly, Fusco and 
colleagues explained that both A and B oligomers can bind to biological membranes, but only B 
oligomers with their rigid β-sheet core are able to get through the lipid bilayer and therefore to 
directly disrupt the membrane (Fusco et al., 2017). According to this model, type A oligomers 
convert into more compact protofibrils and fibrils, thus being responsible for seeding formation of 
new aggregates and αS pathology propagation; type B oligomers are strongly detrimental for 
directly disrupting biological membranes but are off the pathway of self-propagation. In line with 
this view, our research group recently demonstrated that αS species associated to microsomes (a 
membrane fraction including ER, Golgi and synaptic vesicles) had different effects, in terms of 
seeding properties on intracellular aggregates, when they were isolated from sick αS transgenic 
mice with respect to adult but presymptomatic littermates, suggesting the presence of at least two 
different types of αS high molecular weight (HMW) species in vivo, corresponding to different 
stages of αS pathology (Colla et al., 2018). For instance, αS toxic species isolated from diseased 
mice (likely together with αS aggregates) were able to seed for intracellular inclusions and induce 
cell death of primary neurons, whilst αS toxic species isolated from presymptomatic mice caused 















Fig.1.8 αS aggregation process. (Miraglia et al., 2018) In physiological conditions, αS is found as a highly 
disordered monomeric protein in a dynamic equilibrium with a multimeric conformation when bound to 
synaptic vesicles, SV (Weinreb et al., 1996; Fauvet et al., 2012; Burré et al., 2010; Burré et al., 2014; 
Theillet et al., 2016). Other studies proposed that αS in native state is a homo-tetramer and the disruption of 
this conformation causes the increase of the monomeric form (Bartels et al., 2011; Wang et al., 2011; 
Dettmer et al., 2015a, 2015b). αS aggregation is a nucleation process in which soluble monomeric αS is 
converted into insoluble β-sheet rich structures, tightly stacked in a parallel configuration (Lashuel et al., 
2002; Vilar et al., 2008; Tuttle et al., 2016). Based on in vitro studies, we know that these structures account 
a heterogeneous pool of intermediate states named oligomers (Cremades et al., 2012; Chen et al., 2015), 
which generate protofibrils and ultimately aggregates, with a ribbon or a fibril conformation (Bousset et al., 
2013; Guo et al., 2013). Both oligomers and aggregates have been described to be toxic, through different 




αS has been shown to undergo a variety of post-translational modifications, which affect its 
conversion into oligomers and aggregates in different ways. 
 Phosphorylation 
Phosphorylation is the most frequent post-translational modification occurring in proteins at 
serine (S) or tyrosine (Y) residues, in both cases at the level of the hydroxyl group. For what 
concerns αS S129 is the major phosphorylation site, while three others were identified in the last 
years at S87, Y125, Y133 and Y136 (Fujiwara et al., 2002; Anderson et al., 2006; Chen et al., 
2009; Paleologou et al., 2010). Immunohistochemical and biochemical studies have reported that 
~90% of αS found in LBs and LNs is phosphorylated at S129 and the amount of phosphorylated 
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αS in healthy brains is only 4% of total αS, suggesting that the accumulation of pS129-αS is 
involved in the formation of LBs and LNs and the neurodegeneration occurring in PD patients 
(Fujiwara et al., 2002; Zhou et al., 2011). Several kinases were identified for αS. Casein kinases 
(CK1, CK2), G protein-coupled receptor kinases (GRK1, GRK2, GRK5 and GRK6), calmodulin-
dependent kinase (CDK2) and polo-like kinases (PLK2, PLK3) are all possible candidates for 
phosphorylation at S129. The effects of this specific modification on αS propensity to aggregate 
are controversial depending on the specific kinase used for the study. E.g. the phosphorylation at 
S129 by CK2 and GRK6 causes increased oligomerization, fibrillation and neurodegeneration 
(Fujiwara et al., 2002; Sato et al., 2011), whilst phosphorylation at S129 by CK1 inhibits αS 
fibrillation (Paleologou et al., 2008). Specifically, S129 undergoes phosphorylation by CK1 in the 
fibrillary state, which means that this modification occurs after αS fibrillation and/or during the 
development and maturation of LBs and LNs (Paleologou et al., 2008).  
 Ubiquitination 
Ubiquitination is a fundamental biochemical process which regulates a variety of aspects for 
protein function, e.g. degradation, protein-protein interaction and subcellular localization. αS 
contains 15 lysine (K) residues and 9 of them were shown to undergo ubiquitination: K6, K10, 
K12, K21, K23, K32, K34, K45 and K96 (Sampathu et al., 2003; Tofaris et al., 2003; Nonaka et 
al., 2005; Rott et al., 2014). Ubiquitination of αS leads to changes in its activity, affecting its 
localization and degradation processes. Ubiquitination of aggregated or filamentous proteins has 
been implicated in the pathogenesis of many neurodegenerative disorders. Specifically, ubiquitin-
positivity was shown for nuclear inclusion bodies made of expanded polyglutamine repeats in 
many polyglutamine diseases, for neurofibrillary tangles composed of hyperphosphorylated tau in 
Alzheimer’s disease, for LBs and LNs containing hyperphosphorylated αS in α-synucleinopathies 
(Nonaka et al., 2005). Moreover, genetic studies have proved that dysfunctional proteins 
belonging to the ubiquitin-proteasome pathway are responsible for neurodegeneration. The 
ubiquitination modulated by SIAH-2, an E3 ubiquitin-ligase which mono and di-ubiquitinate αS 
in vivo, is similar to the endogenous ubiquitination pattern observed in biochemically purified 
LBs and involves K12, K21 and K23 residues. Under conditions of proteasomal impairment, 
SIAH-1, another E3 ubiquitin-ligase, promotes αS aggregation and apoptotic cell death (Rott et 
al., 2008; Beyer and Ariza, 2013). 
 Nitration and oxidation 
Cellular oxidative damage occurs when the production of reactive oxygen species overcomes the 
compensatory antioxidant capacity of the cell itself. A common consequence of increased 
oxidative stress is the nitration of tyrosine residues caused by peroxynitrite, a reaction product 
generated after combining oxygen and nitric oxide. αS contains four tyrosines (Y39, Y125, Y133 
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and Y136) which can all undergo nitration (Duda et al., 2000; Giasson et al., 2000; Burai et al., 
2015) and four methionines (M1, M5, M116 and M127) which can all be subjected to oxidation 
under conditions of oxidative stress (Beyer and Ariza, 2013; Barrett and Timothy Greenamyre, 
2015). It has been claimed that the abnormal levels of oxidative stress occurring in DA neurons 
are a major cause for PD progression. LBs are found enriched of nitrated αS and when this is 
administrated to the SNpc of rats, it leads to a strong reduction in DA neurons number (Yu et al., 
2010). It has been suggested that the susceptibility of this neuronal type to αS pathology may be 
due to the fact that αS oxidation causes the accumulation of DA-αS toxic adducts. Furthemore, 
when nitrated αS is administred to cultured cells, it causes apoptosis in a dose-dependent manner 
through the formation of nitrated αS oligomers (Liu et al., 2011). 
 Truncation 
Different studies have reported a variety of specific sites for αS truncation (E110, D115, D119, 
P120, E130, Y133 and D135), all of which are found in the C-terminal region of the protein (Li et 
al., 2005; Liu et al., 2005; Lewis et al., 2010), although N-terminal truncation can also happen. 
The three main truncated fragments identified in vivo are referred to as Syn12, Syn10, Syn8. 
Syn12 and 10 are generated after truncation at P120 and E110 residues respectively, whilst Syn8 
is the result of a double truncation at N- and C-terminal and is a fragment of about 80 aminoacids. 
Syn12 and 10 are present in both detergent soluble and insoluble fractions from mouse and human 
brains, whereas Syn8 is only present in the insoluble fraction and is specific for diseased brains. 
Furthermore, it has been shown that the accumulation of Syn12 and 10 occurs independently from 
of αS aggregation, while Syn8 needs the aggregation of αS in order to accumulate. αS truncation 
can be mediated by more than one proteolytic system, including 20S proteasome, Calpain I, 
Cathepsin D, Neurosin and Matrix Metalloprotease 3 (Li et al., 2005; Beyer and Ariza, 2013). The 
truncated forms Syn12 and 10 are known to be generated also under physiological conditions, 
nevertheless the amount of truncated αS strongly increases in case of genetic PD. Moreover, these 
truncated species preferentially accumulate in αS aggregates, especially the ones not associated 
with membranes (Colla et al., 2018), and have the ability to enhance fibril formation from full 
length αS (Li et al., 2005).  
 Other modifications 
Other post-translational modifications have been negatively correlated to αS pathology, meaning 
that they inhibit its propensity to aggregate. For this reason, studying these modifications can be 
useful for finding protective pathways for α-synucleinopathies and also for better understanding 
the modulators of αS physiological role. Lysine acetylation is a post-translational modification 
involved in several physiological functions. For what concerns αS, four residues have been shown 
to undergo acetylation (K6, K34, K45 and K97) (Lundby et al., 2012). N-terminal acetylation is a 
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very common modification of mammalian αS which stabilizes its native structure, thus inhibiting 
aggregation (Bartels et al., 2014). 
Another modification which has been associated to PD and affects αS conformation is the 
transglutaminase-induced cross-linking. Transglutaminases are enzymes which catalyze the 
formation of an isodipeptide by linking one glutamine to one lysine. When these residues are on 
the same protein, like for αS, the effect is an intramolecular cross-linking, which leads to the 
formation of a more compact monomer. The consequence of this compact conformation is the 
inhibition of oligomerization, fibrillization and membrane binding of αS in vitro. Specifically, 
Schmid and colleagues have shown that the major transglutaminases substrates in αS sequence are 
the glutamine residues Q79 and Q109 which can cross-link to various lysine residues in the N-
terminal region, and up to three intramolecular cross-links can occur on a single monomer 
(Schmid et al., 2009). 
Sumoylation is a post-translational modification which consists in the attachment of small 
ubiquitin-related modifier (SUMO) and can affect a variety of cellular mechanisms. Sumoylation 
was recently suggested to be a solubility promoter of aggregation-prone proteins. αS has been 
reported to be sumoylated at two sites (K96 and K102) upon overexpression and whilst 
unmodified αS can form fibrils, sumoylated αS remains soluble. Moreover, the presence of as 
little as 10% sumoylated protein was shown to be enough to delay the aggregation process in vitro 
(Krumova et al., 2011). Another study demonstrated that SUMO binding regulates sorting of 
proteins (including αS) in extracellular vesicles, revealing another putative function of 
sumoylation as a ubiquitin-independent sorting signal (Kunadt et al., 2015). 
 
 
Fig.1.9 Post-translational modifications of αS. The complete 140 aminoacids sequence of αS is depicted 
and the sites where the modifications occur are highlighted. P in yellow for phosphorylation, Ub in blue for 
ubiquitination, NO2 in purple for nitration, Ox in white for oxidation, the scissors in grey for truncation, Ac 
in red for acetylation, TG in orange for transglutaminase cross-linking, SUMO in green for sumoylation. 
Specifically, the group of post-translational modifications represented in circles are known to promote αS 





αS mechanisms of toxicity 
 
As mentioned before, ubiquitination is a modification involved in many regulatory functions 
fundamental for cellular survival, among which protein degradation. Specifically, protein 
degradation mechanisms within the cell mainly consists in the ubiquitin-proteasome system and 
the autophagic-lysosomal pathway. For what concerns αS, the former is responsible for the 
degradation of oligomers, the latter for the degradation of aggregates (Tetzlaff et al., 2008). When 
the aggregation process driven by αS overexpression occurs, both systems can become 
dysfunctional. In fact, different in vitro studies showed the inhibition of proteasomal function 
(Petrucelli et al., 2002), impairment of chaperone-mediated autophagy (Yang et al., 2009; Song et 
al., 2014) and macroautophagy (Winslow et al., 2010) caused by αS overexpression. 
As previously explained, αS binds to lipid membranes in both physiological and pathological 
conditions. While cytosolic and membrane bound states are both physiologically relevant, it is 
unclear how their localization affects αS pathology and where aggregation initiates. A variety of 
studies has shown that membrane binding and lipid interaction can stimulate but also inhibit αS 
fibrillation (Narayanan and Scarlata, 2001; Lee et al., 2002a; Jo et al., 2004; Burré et al., 2015; 
Galvagnion et al., 2016). In line with this controversy it has been observed that SNCA point 
mutations associated with familial PD are located in the N-terminal lipid binding domain, 
suggesting that lipid binding may be related to αS acquired toxicity. This happens for some point 
mutations such as A30P, in which membrane binding is reduced and aggregation is increased, but 
not for others. For instance, A53T, E46K and H50Q mutations cause a higher fibril formation 
without affecting lipid binding (Bussell and Eliezer, 2004; Fredenburg et al., 2007; Khalaf et al., 
2014); others such as G51D inhibit both membrane binding and aggregation (Fares et al., 2014). 
Thus, lipid binding and αS aggregation not always correlate directly, but other factors can 
influence the propensity of the protein toward fibrillation and compensate for aminoacid 
substitutions, such as intramolecular interaction between the N- and C-terminal or protein binding 
to the C-terminal (Ulrih et al., 2008; Burré et al., 2010). Moreover, the aforementioned αS post-
translational modifications induced by oxidative stress have been shown to increase 
oligomerization and possibly to influence αS ability to bind vesicle membranes as a monomer or 
in an oligomer conformation (Binolfi et al., 2006; Xiang et al., 2013; Follmer et al., 2015; 
Plotegher et al., 2017). In this complex situation, it is clear that interaction with biological 
membranes leads to modifications not only for αS conformation, but also for the physical 
properties of the membranes. For instance, it induces changes in melting temperature (Galvagnion 
et al., 2016) and membrane remodelling (Jiang et al., 2013) such as lateral expansion of 
membrane lipids and lipid packing modifications (Ouberai et al., 2013). Membranes of specific 
organelles such as ER, mitochondria, Golgi and synaptic vesicles have been shown to be 
associated at different extent with αS. After focusing on the physiological aspects, we will now 
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consider the pathological mechanisms of αS deriving from these subcellular associations. 
 ER and Golgi 
αS has been found associated with ER and Golgi in mice and human cell cultures. Specifically, 
microsomes-associated αS was proved to be partially protected from protease K digestion and 
thus connected with the lumenal side of the microsomes (Colla et al., 2012a). Although no lipid 
binding involvement has been described yet, αS was found to bind, in αS Tg mice and human cell 
lines overexpressing αS, to gpr78/BIP, a chaperone bound to the luminal side of the ER, 
transiently associated with the ER translocon import pore and directly implicated as a sensor of 
protein misfolding and initiator of the unfolded protein response (Bellucci et al., 2011; Colla et 
al., 2012b). Additionally, the overexpression of αS impaired the ER-Golgi vesicular trafficking in 
yeast and other organisms (Cooper et al., 2006), leading to the accumulation of ER proteins with 
induction of ER stress, Golgi fragmentation and depletion of lysosomal enzymes (Oaks et al., 
2013; Mazzulli et al., 2016). Interestingly, this detrimental effect was rescued by overexpressing 
proteins implicated in vesicle transit from the ER to the cell membrane such as Rab1 (ER-Golgi), 
Rab8 (Golgi) and Rab3A (post-Golgi) (Gitler et al., 2008) but also from endolysosomal pathway 
such as Rab-11A (endosomal recycling) (Breda et al., 2015). Another study showed that αS 
oligomers in vitro decrease axonal transport and influence microtubule stability (Prots et al., 
2013). These observations have strong implications for a major role of αS in vesicle trafficking 
and recycling, outside the synapses. 
 Mitochondria 
Other studies showed that αS can bind the outer and inner membrane of mitochondria (Devi et al., 
2008; Nakamura et al., 2008). Since these data were obtained from in vivo observations, it is not 
clear whether the binding depended on lipids, in line with αS preference for cardiolipin, abundant 
in the mitochondrial membranes, or it was mediated by specific proteins. Interestingly, a 
translocase of the mitochondrial outer membrane has been described as responsible for the import 
of αS into the mitochondria and one of its subunits, TOM20, has been shown to bind αS in vivo 
(Di Maio et al., 2016). Additionally, the overexpression of αS was found to promote 
mitochondrial dysfunction in αS Tg mice (Martin et al., 2006, 2014) and mitochondrial 
fragmentation in primary neurons. This latter effect was related to the direct interaction of αS with 
mitochondria, since disruption of αS N-terminal membrane binding domain restored the 
morphology of the organelles (Nakamura et al., 2011). Particularly toxic to mitochondria are αS 
oligomers, associated to the inhibition of complex I with subsequent increase of reactive oxygen 
species and oxidative stress (Cremades et al., 2012; Devi et al., 2008), to the alteration of 
membrane potential and Ca
2+
 homeostasis, to mitochondrial fragmentation (Nakamura et al., 
2011), to mitochondrial protein import impairment (Di Maio et al., 2016), to the externalization of 
28 
 
cardiolipin toward the outer mitochondrial membrane resulting in mitophagy for cellular stress 
(Ryan et al., 2018). 
 Synaptic vesicles 
As explained before, αS binds vesicles at the synapse and acts as a molecular chaperone to 
promote SNARE complex assembly (Burré et al., 2010), which is necessary to regulate docking 
and neurotransmitter release and reuptake. Following αS overexpression, the SNARE assembly is 
blocked and the whole process is impaired (Majd et al., 2015). 
Other studies based on exogenous administration of large oligomers of recombinant αS at the 
synapse, showed that αS bound to synaptic vesicles through synaptobrevin-2, leading to inhibition 
of vesicle docking to the membrane (Choi et al., 2013) and to lower synapsins abundance (Larson 
et al., 2017). Although direct measurement of ER-Golgi traffic was not assessed in these 
conditions, it is plausible that accumulation of toxic species of αS might affect the whole protein 
transport system from the ER to the membrane. Moreover, electrophysiology studies showed that 
αS oligomers impaired long-term potentiation (Diogenes et al., 2012; Martin et al., 2012) and 
reduced neuronal excitability (Kaufmann et al., 2016). 
 
Overall it is not clear where αS detrimental effects begin, although it is plausible to hypothesize 
that the initial pathogenic transition of αS toward a toxic conformation may occur in proximity of 

















Fig.1.10 Subcellular localization of αS oligomers and aggregates in physiological and pathological 
conditions. αS capability of binding membranes has been correlated to part of its physiological roles and 
specifically several studies have shown how this protein can bind to synaptic vesicles, ER/Golgi and 
mitochondria (Devi et al., 2008; Nakamura et al., 2008; Burré et al., 2010; Colla et al., 2012a). Up to date it 
is still under debate whether αS association with membranes contrasts or promotes its aggregation, 
nevertheless it is clear that the accumulation of αS toxic species at these specific subcellular sites leads to 
precise cellular dysfunctions involving neurotransmission, protein trafficking and mitochondrial respiration 
(Miraglia et al., 2018). 
 
 
Lewy pathology in the periphery and Braak model 
 
A turning point for the debated link between PD and GI symptoms occurred in 2003. The finding 
that LBs and LNs present in the brains of patients (Spillantini et al., 1997) were also present in 
specific districts of the PNS and specifically in the ENS in PD patients as well as in healthy 
individuals (Braak et al., 2003a), led to the development of the Braak model. Braak and 
colleagues suggested that Lewy pathology in PD patients develops following a stereotypic 
temporal pattern, with a caudo-rostral progression over time. According to this model, the 
neuropathology can be divided into six stages, accounting both presymptomatic and symptomatic 
phases (Braak et al., 2003a, 2003b). At the beginning (stage 1), LBs and LNs appear in two sites: 
the ENS, linked to the dorsal motor nucleus of the vagus nerve (dmX) and the olfactory bulb, in 
the anterior olfactory nucleus. At stage 2 the pathology is diffused within the medulla (in the 
gigantocellular reticular nucleus) and the pons (in the lower raphe nuclei and the locus coeruleus). 
These three nuclei together form the gain setting system, which receives major inputs from 
components of the limbic and motor systems, such as the central subnucleus of the amygdala. 
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This system can control the incoming pain signals during stress and ensures that motor neurons 
are ready for action. The descending fibers of the gain setting system form a sensory control 
network for both somato and visceromotor efferents, enabling the body for momentary demands. 
During stage 3, Lewy pathology spreads caudo-rostrally from the brainstem to the mesencephalic 
tegmentum and basal regions of the prosencephalon. A process of neuronal cell death starts in the 
central subnucleus of the amygdala and the magnocellular cholinergic nuclei of the basal 
forebrain. In fact, the central subnucleus of the amygdala projects to the gain setting system and 
the dmX, and in turn it receives projections from the amygdalar basolateral complex, which 
receives strong inputs from the magnocellular nuclei of the basal forebrain. Only at stage 4 the 
patients begin to experience motor dysfunctions, entering the so called symptomatic phase. The 
pathology hits the SNpc and the temporal mesocortex, which projects all signals from the 
neocortex to the centers of the limbic circuit (amygdala, hippocampal formation, entohirnal 
region) and prefrontal cortex. Among the cortical sites, the temporal mesocortex is the most 
affected in PD. Ultimately (stages 5 and 6) Lewy pathology reaches the neocortex (in the high-
order sensory association and prefrontal areas) and the patients develop more severe motor 
symptoms, together with cognitive dysfunctions. The first order sensory association areas, 
premotor fields and finally the primary sensory and motor fields become affected. 
 
Fig.1.11 Staging of αS pathology in PD 
according to the Braak model. As 
summarized in the scheming, Braak and 
colleagues proposed that the pathological 
process of αS in PD starts in the PNS and 
specifically the ENS, gaining access to the 
CNS through the dmX in the lower 
brainstem. From here, the pathology spreads 
upwards through vulnerable regions of the 
medulla oblongata, pontine tegmentum, 
midbrain and forebrain, and ultimately 
reaches the cerebral cortex (Braak et al., 






Along with this staging model, Braak and colleagues speculated on the origin of the pathology in 
the first place, arising the so called dual-hit theory. Based on the location of the first appearances 
of LBs and LNs, the ENS and the olfactory bulbs, they suggested that idiotpatic PD may start 
with an infiltration of a neurotropic pathogen at these two sites (hence dual-hit). More precisely, 
according to this theory, the pathogen would enter the human body through the olfactory pathway, 
in the respiratory system, and through the gut pathway, by swallowing the saliva containing nasal 
secretions. The already described olfactory and GI symptoms, which occur very early during the 
prodromal phase of PD, stand in support of this theory. As previously mentioned, the nasal route 
is used to explain the early involvement of olfactory structures, although Braak and colleagues do 
not think this is the starting point for αS pathological spreading within the CNS. In fact, Lewy 
pathology appears in the anterior olfactory nucleus and olfactory bulb at first and subsequently 
closely related olfactory areas, but the lesions do not advance further into non olfactory cortical 
areas. Rather, all patients analyzed show neocortical involvement only after the appearance of 
lesions in the anteromedial temporal mesocortex. A prerequisite for neocortical affection appears 
to be that the subcortical lesions have expanded to such an extent that they include the 
magnocellular nuclei of the basal forebrain. Therefore, the leading predilection sites of the 
pathological process are located in the lower brainstem. They suggest that the GI tract is the site 
of departure for the Lewy pathology, where the pathogen is thought to cross the mucosal and 
epithelial barriers, thus reaching the neuronal structures. The nature of this pathogen is still 
debated, it has been speculated that it could be a neurotropic virus capable of infecting specific 
vulnerable neurons, or αS itself (misfolded or fragmented) through a prion-like mechanism (Braak 





















Fig.1.12 Properties required for misfolded proteins to be transmissible. Efficient replication, which 
occurs thanks to the seeding-nucleation process. Resistance to biological clearance, e.g. proteasomal 
degradation, chaperone refolding, autophagy. Biovailability (ability to reach the target tissue and cellular 
location) through cellular transport and spreading, and penetration across the enteric and blood-brain 
barriers. Transmission of phenotypic changes, where for disease-associated misfolded proteins the changes 
are cellular damage, tissue dysfunction, and clinical disease; for functional transmissible proteins, the 
phenotypic change is the modulation of a biological activity or acquisition of a new function (Soto, 2012). 
 
After Braak, different studies have corroborated his hypothesis, by finding LBs and LNs in 
several districts along the ENS (Lebouvier et al., 2008; Beach et al., 2010; Gelpi et al., 2014). In 
the meantime, several research groups have implicated αS neuronal transmission and propagation 
within the nervous system as a mechanism of detrimental spreading of PD pathology, showing 
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that neuron-to-neuron transfer of pathogenic αS occurs both in vitro (Luk et al., 2009; Volpicelli-
daley et al., 2012; Colla et al., 2018) and in vivo, in human (Kordower et al., 2008a, 2008b) and 
animal studies (Kordower et al., 2012; Luk et al., 2012; Masuda-Suzukake et al., 2013; Rey et al., 
2013; Holmqvist et al., 2014; Recasens et al., 2014; Sacino et al., 2014; Peelaerts et al., 2015), 
supporting the hypothesis that the accumulation of toxic αS species may originate outside the 
CNS and later move to the brain using anatomical connections (Braak et al., 2003b; Hawkes et al., 
2009). In PD patients, pathological αS has been found in enteric neurons of both submucosal and 
myenteric plexi along the entire GI tract including the colon (Böttner et al., 2012; Gelpi et al., 
2014). Another study found a rostro-caudal gradient of accumulation of pS129-αS within the ENS 
with a higher incidence of LBs in the lower esophagus and submandibular gland and to a less 
extent in the colon and rectum (Beach et al., 2010). Although this observation has to be confirmed 
in a larger population, the involvement of the vagal nerve, which innervates directly the stomach, 
the small intestine and the ascending colon, as the main dissemination route of toxic αS along the 
gut-brain axis, has been suggested, based also on the finding of LBs presence in the dmX in 
prodromal PD (Braak et al., 2003a). However, the high incidence of aggregated αS in the all 
segments of the spinal cord suggests that other nerves might be implicated in αS propagation 
(Böttner et al., 2012). Several studies have indicated LBs presence in human colon biopsies as a 
possible diagnosis method for preclinical PD (Lebouvier et al., 2008; Pouclet et al., 2012; 
Shannon et al., 2012), although other observations are against this hypothesis (Böttner et al., 
2012; Visanji et al., 2015). Overall, detecting pathological αS in the gut as a potential biomarker 
for PD patients is still challenged by the heterogeneity of antibodies, antigen retrieval methods 
and GI sites analysed, therefore the discrepancy among these studies should be interpreted 
cautiously. This is only one example that easly explains why for a great number of human 
pathologies and in particular neurodegenerative diseases, animal studies are always needed to be 
carried out, in parallel to clinical studies. Unfortunately, whether there is a direct pathogenic 
correlation between GI dysfunction and PD or not, to date still remains an open issue, caused in 
part by the absence of appropriate animal models that recapitulate the chronic and progressive 
development of PD pathological stages. All the αS Tg mouse lines analyzed for constipation so 
far showed GI deficit only concurrent with CNS neuropathology (Wang et al., 2008; Kuo et al., 
2010; Hallet et al., 2012), while when considering the pharmacologically induced PD models only 
a small study, based on chronic injections of rotenone at low dosage in rats, showed mild GI 
abnormalities in absence of CNS αS pathology. Nevertheless, because of the low amount of 
rotenone used for this purpose, brain pathology and motor symptoms never occurred in these mice 





The enteric nervous system 
 
The gut is an extremely complex system responsible for a variety of functions related primarly but 
not only to digestion, such as absorption, secretion, motility, mucosal maintenance and 
immunological defense. All these functions require a fine degree of regulation and coordination, 
provided by the ENS. The ENS is, within the PNS, one of three divisions of the autonomic 
nervous system, named sympathetic, parasympathetic and enteric (Rao and Gershon, 2016). 
 
 
Fig.1.13 Organization of the PNS and the ENS. The nervous system is divided in CNS and PNS (green). 
Afferent information from the periphery to the CNS is conveyed by neurons located in dorsal root or cranial 
nerve ganglia, which constitute the sensory division of the PNS (yellow). These inputs integrated by the 
CNS leads to outputs through the motor division of the PNS (blue). Efferent projections from the CNS 
target either skeletal muscles or the autonomic nervous system, which is further divided into sympathetic, 
parasympathetic and enteric. Unlike neurons in sympathetic or parasympathetic ganglia, the majority of 
enteric neurons do not receive direct innervation from the CNS. In fact, the ENS contains primary afferent 
neurons able to respond intrinsically to local stimuli, thus integrating information and coordinating motor 
output independently from the CNS. This gives to the ENS unique sensory and motor properties, although 





The ENS is responsible for the innervation of the whole digestive tube, from the esophagus to the 
rectum, and is organized into two plexi. The myenteric plexus (or Auerbach's plexus) is the main 
player for GI motility, in fact it lies between the longitudinal and circular smooth muscle layers to 
which it provides motor innervation, with both parasympathetic and sympathetic inputs. 
The submucosal plexus (or Meissner’s plexus) is located in the dense connective tissue of the 
submucosa just underneath the mucosa, it has only parasympathetic fibers and is the main 
responsible for GI secrection and absorbtion. 
 
 
Fig.1.14 The ENS architecture through the gut 
layers. Schematic view of the intestine illustrating 
the organization of the ENS and its location within 
the enteric wall. The myenteric plexus is located 
between the longitudinal and circular smooth 
muscle layers, whilst the submucosal plexus is 
located in the submucosa, underneath the mucosa. 
There are not nerve fibers entering the lumen or its 
epithelial lining. The extrinsic innervation reaches 
the gut through the mesentery together with the 
vascular system (Rao and Gershon, 2016). 
 
 
In humans, the ENS accounts more than 100 million neurons, more than the other peripheral 
ganglia altogether, and at least as many as the spinal cord. Interestingly, with this size the ENS 
dwarfs the number of efferent vagal fibers projecting to almost all the digestive tract, from the 
esophagus to the proximal colon. It is important to mention that in addition to the vagus nerve, the 
splanchnic, mesenteric and pelvic spinal nerves are deputate to the innervation of the abdominal 
viscera (Furness, 2006; Forsythe et al., 2014). Unlike the rest of the PNS, the enteric division is 
capable of integrating neuronal activity, that is combining a variety of inputs into coherent 
behavioural outputs and regulating GI functions independently from CNS inputs. In fact the ENS 
is organized in microcircuits, with interneurons and intrinsic primary afferent neurons, capable of 
initiating reflexes (Furness et al., 2014). A great neuronal phenotypic diversity is not prerogative 
of the CNS, since most of the neurotransmitters active at the central level are also present in the 
ENS, with few differences (Furness, 2000; Furness et al., 2014). For what concerns peristalsis, the 
motor activity of the bowel is mainly regulated by the cholinergic and tachykinergic systems for 
contraction, and by the nitrergic system for relaxation (Mang et al., 2002; Bornstein et al., 2004). 
Notably, DA contribution to intestinal function in the lower digestive tract is negligible and the 
presence of DA neurons at this level is highly debated (Bornstein et al., 2004). 
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Although the ENS is capable of working regardless central inputs, normally the CNS influences 
GI behaviour, and the gut in turn sends information to the brain. More precisely, 90% of vagal 
fibers connecting the gut to the brain are afferent, suggesting that the CNS plays more the role of 
receiver rather than transmitter in this cross-talk. For example, gut-to-brain signalling carries 
sensations such as nausea, bloating and satiety, although much of this information has a 
homeostatic nature and does not reach consciousness. Actions such as mastication and 
swallowing are CNS-dependent instead, and efferent signals brain-to-gut are important for gastric 
motility control. On the other hand, the movements of the small and large intestine are under the 
control of the ENS and this is why even if all connections to the CNS are severed, essential 





Aim of the project 
 
The aim of this project was to characterize GI function in a mouse model of α-synucleinopathy 
originally developed to study neurodegeneration in the CNS. Because this model develops αS-
induced central dysfunction in adult age (after 9 months) our purpose was to characterize 
peripheral abnormalities before the onset of central neurodegeneration and overt motor 
dysfunction, to describe the nature of such alterations and to determine whether this dysfunction 
was ascribable to αS overexpression or pathology. Ultimately we exploited silenced αS 








Matherials and methods 
 
Mice 
For this research we used Tg mice expressing human A53T αS under the control of the mouse 
prion protein (PrP) promoter (line G2-3) (Lee et al., 2002b; Martin, 2006). This model develops 
neurological abnormalities after 9 months of age (with an average peak at ~13 months) that 
manifest initially with reduced locomotion, wobbling, lack of balance and weakness of the hind 
limbs. This diseased phenotype becomes progressively more severe culminating into a fatal 
paralysis within 14-21 days from the first symptoms appearance. Because of the high variability 
in time of onset (between 9 to 16 months), Tg mice are closely monitored after 9 months of age, 
being aware that once the first symptoms appear, the animal is committed to develop the full 
phenotype. Diseased mice show an accumulation of intracellular, phosphorylated (S129) and 
ubiquitinated αS inclusions, neuroinflammation and neuronal degeneration in the CNS (Lee et al., 
2002b). For the purpose of this study, sick Tg mice at 12-14 months, presymptomatic mice at 1, 2, 
3, 6, 9 and 12 (if still healthy) months, and age-matched nTg littermate controls were used. All 
animal studies were approved by and complied in full with the national and international laws for 
laboratory animal welfare and experimentation (EEC council directive 86/609, 12 December 1987 
and Directive 2010/63/EU, 22 September 2010). 
 
 
Fig.2.1 Images depicting a Tg mouse during presymptomatic phase, without motor disfunction (A) and a Tg 






Behavioral tests and additional parameters 
All tests for behavioral and additional parameters were carried out on groups of 20-30 mice, 
except for gait test, food intake and glycemia where groups consisted of  ~10 mice each. Both 
male and female animals were used. Each trial was performed 1 to 3 times per animal on non 
consecutive days. 
 Gait test 
The gait test was assessed in mice after o/n starvation. Each animal’s paw was painted with blue 
washable paint and the mouse was allowed to walk onto a white paper strip, at the end of which a 
piece of chow was placed as a reward. The footprints were circled and let dry. Stance length, 
sway distance and stride length were measured for each mouse. 
 Whole gut transit time 
Whole gut transit time (WGTT) was assessed in mice after oral gavage of 0.05 mL chocolate milk 
containing 4% of brilliant blue food dye. Post-gavage, the animals were observed until the time of 
excretion of the first blue stool, which was recorded for each mouse. 
 Stool collection 
Stool collection assays were performed between 9:00 AM and 11:00 AM on each day. Each 
animal was removed from its home cage and placed in a clean plastic cage without food or water 
for 1 h. Stools were collected immediately after expulsion and placed in sealed tubes. At the end 
of the trial, stools were counted, measured in length and weighted (total weight). After o/n drying 
at 65 °C stools were weighted again to provide dry weight. Water content was calculated as 
difference between total weight and dry weight.  
 Food intake 
Each animal was removed from its home cage and single-housed for 24 h with free access to food 
and water. Food was weighted before and after the trial and food intake was calculated as 
difference between the two amounts.  
 Glycemia 
Glucose levels were assessed using reactive stripes (OneTouch Verio, LifeScan Italia, Milan, 
Italy) with a single drop sample of blood taken from the tail of each animal. Glucose level was 
analyzed after o/n food removal (fasted condition) and after the mice were allowed free access to 




Recording of contractile activity from longitudinal and circular muscle 
preparations of colon and ileum 
Contractile activity was recorded from colonic and ileal longitudinal and circular smooth muscles 
(Antonioli et al., 2014, 2017). Mice were euthanized through CO2 inhalation. After sacrifice, 
colon and ileum were removed and placed in cold Krebs solution. Longitudinal and circular 
muscle strips of the intestine were set up in organ baths containing Krebs solution at 37 °C, 
bubbled with 95% O2 + 5% CO2. The strips were connected to isometric force transducers 
(2Biological Instruments, Besozzo, Italy). Mechanical activity was recorded as a measure of 
tension using a BIOPAC MP150 system (2Biological Instruments). A pair of coaxial platinum 
electrodes was positioned at a distance of 10 mm from the longitudinal axis of each preparation to 
deliver transmural electrical stimulation (ES) by a BM-ST6 stimulator (Biomedica Mangoni, Pisa, 
Italy). ES were applied as 10-s single trains consisting of square wave pulses (0.5 ms, 30 mA). To 
measure muscle contractility of the colon or the ileum, electrically evoked motor responses were 
recorded from tissue preparations maintained in standard Krebs solution. To measure the 
neurogenic contribution to muscle contraction, electrically evoked motor responses were recorded 
after selective stimulation of the nitrergic, cholinergic or NK1-mediated tachykinergic pathway 
from colonic preparations maintained in Krebs solution containing respectively: guanethidine (10 
µM), L-732,138 (10 µM), GR159897 (1 µM), SB218795 (1 µM) and atropine (1 µM) in order to 
inhibit the noradrenergic, NK-mediated tachykinergic and cholinergic pathways, while recording 
the nitrergic signal; L-NAME (100 µM), guanethidine (10  µM), GR159897 (1 µM), SB218795 
(1 µM) and atropine (1 µM) in order to prevent the recruitment of the nitrergic, noradrenergic, 
NK2 and NK3-mediated tachykinergic and cholinergic systems, while recording the NK1-
mediated tachykinergic pathway; L-NAME, guanethidine, L-732,138, GR159897, SB218795, in 
order to record the cholinergic response while inhibiting the nitrergic, noradrenergic and 
tachykinergic signal. To evaluate myogenic contribution to the total contractile activity of the 
colon, muscle response was evoked by direct pharmacological activation of muscarinic receptors 
located on smooth muscle cells. For this purpose, colonic preparations were maintained in Krebs 
solution containing tetrodotoxin (1 µM) and stimulated with carbachol (10 µM). The tension 
developed by each preparation (g) was normalized by the wet tissue weight (g/g tissue). All the 





Tissue collection and immunoblot analysis 
For biochemical analysis mice were euthanized through CO2 inhalation and the intestine was cut 
into six segments corresponding to duodenum (D), jejunum (J), proximal ileum (PI), distal ileum 
(DI), proximal colon (PC) and distal colon (DC), flushed of fecal contents, opened longitudinally, 
scraped for removing the epithelium and minced. Cold phosphate-buffered saline (PBS), with 
proteases and phosphatases inhibitors, was used for this procedure. All samples were frozen on 
dry ice right after collection and stored at -80°C until use. Frozen intestine segments were 
homogenized using a Potter-Elvehjem Grinder homogenizer on ice in 20% (w/v) TNE lysis buffer 
(50 mM Tris-HCl pH 7.4, 100 mM NaCl, 0.1 mM EDTA) with proteases and phosphatases 
inhibitors. Equal volume of TNE buffer containing 2% of NP-40 was added to initial 
homogenates that were then centrifuged at 10,000 x g at 4 °C in order to collect NP-40 soluble 
and insoluble fractions. Pellets were then washed one time with TNE buffer with 1% of NP-40 
and then resuspended in 10% of the original homogenization volume in TNE containing 1% NP-
40, 1% SDS, 0.1% DOC. NP-40 insoluble fractions were then sonicated and boiled for 5 min at 
95°C.  
 
Fig.2.2 Scheming for the harvesting procedure of mice intestine. Six segments corresponding to 
duodenum (D), jejunum (J), proximal ileum (PI), distal ileum (DI), proximal colon (PC) and distal colon 
(DC) were collected, homogenized and fractionated into NP-40 soluble and insoluble components, 





Protein amount was determined with BCA. For western blot, protein lysates together with SDS-
PAGE sample buffer were run on a 4–20% Criterion™ TGX™ Precast Midi Protein Gel (Bio-
Rad, Hercules, CA, USA) and then transferred onto nitrocellulose membrane at 200 mA, o/n at 
4°C, using carbonate transfer buffer (10 mM NaHCO3, 3 mM Na2CO3, 20% MeOH). Transfer 
efficiency was controlled by Ponceau staining. For dot blot, 2 µg of protein lysates were spotted 
directly onto nitrocellulose membrane. Thereafter, for both western blot and dot blot, unspecific 
binding sites were blocked by 30 min membranes incubation with 5% non fat dry milk (Bio-Rad) 
in 1X PBS containing 0.01% Tween-20 (PBS-T) at RT. Membranes were then incubated with the 
specific primary antibody dissolved in 2.5% non fat dry milk in PBS-T, o/n at 4°C. The following 
antibodies were used: Syn1, pS129-αS, GAPDH, α-Tubulin for western blot and Syn303 for dot 
blot. Membranes were washed with PBS-T and incubated for 1 h at RT with the appropriate 
horseradish peroxidase-conjugated secondary antibody in 2.5% non fat milk in PBS-T. Only for 
pS129-αS detection, 1X Tris-buffered saline containing 0.01% Tween-20 (TBS-T) instead of 
PBS-T was used for the entire procedure. The chemiluminescent signals were visualized using a 
CCD-based Bio-Rad Molecular Imager ChemiDoc System (Bio-Rad). Band intensities were 
analyzed using Quantity One software (Bio-Rad). 
 
Immunofluorescence analysis 
For immunofluorescence analysis, mice were perfused with 4% PFA/PBS after 1 mL 
intraperitoneal injection of 2% w/v Tribromoethanol. Brain and colon (flushed of fecal contents) 
were collected, post-fixed o/n in 4% PFA/PBS at 4°C and stored in maintenance solution (30% 
sucrose, 0.1% NaN2 in PBS) at 4°C. A segment of 2 cm of distal colon was embedded in Tissue-
Tek® OCT (Sakura, The Netherlands), cut at the cryostat in serial 12 µm sections and mounted 
on SuperFrost Plus glass slide (Thermofisher). For one experiment, the whole distal colon was cut 
longwise and mounted on a toothpick according to the “Swiss roll” technique, before 
cryosectioning. The slides were washed with PBS and let dry for ~3 h at 37°C before staining. 
Brains were cut at the microtome in serial 30 µm sections and placed in 24-well plates containing 
maintenance solution. The slices were washed with PBS before staining. For both colon and brain 
samples, the sections were incubated with blocking solution [3.5% non fat dry milk, 0.3% Triton 
X-100 (Tx-100), 6% normal goat serum in PBS] for 1 h at RT and then incubated with primary 
antibody o/n at RT in blocking buffer. The following antibodies were used: pS129-αS, LB509, β-
3-Tubulin, Syn204, Choline Acetyltranferase (ChAT), Tyrosine Hydroxylase (TH), 
Neurofilament H (NF200), Synaptic Vesicle 2 (SV2). On the next day, the sections were washed 
twice in PBS and incubated with Alexa Fluor secondary antibodies or Streptavidin 
(ThermoFisher) in PBS containing 1.5% NGS, 0.3% Tx-100 for 1 h at RT. The sections were 
counterstained with DAPI and mounted on a glass slide using Fluormount (Sigma-Aldrich). 
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αS at S129 
1:2000 WB 
1:5000 IF 
Rabbit Abcam MA, USA 51253 WB, IF 











Human αS AA 
115-122 




















































Tab.2.3 List of antibodies employed for western blot (WB), dot blot (DB) and immunofluorescence (IF) 




The antisense oligonucleotides (ASOs) were synthesized and provided by Eurogentec (Liege, 
Belgium) and Integrated DNA Technologies (San Jose, CA, USA). Each ASO was a sequence of 
20-base pairs with a phosphorothioate backbone. Following a gapmer design, a 2’-O-
methoxyethyl (2’-MOE) modification was added on the sugar of the first and the last 5 
nucleotides, leaving the middle 10 nucleotides unmodified at the 2’-sugar position. For the 
experiment in vitro, 1 scramble ASO control and 3 ASOs against αS were used (ASO 1, 2, 3), the 
first two targeting human A53T αS, the last one targeting both human A53T and mouse αS. For 




SH-SY5Y human neuroblastoma cells were plated in 6-well culture plates and maintained using 
Dulbecco’s Modified Eagle’s Medium F12 (DMEM-F12; Sigma-Aldrich, St. Louis, USA) 
with 10% FBS, 0.1 mg/ml of streptomycin and 100 U/ml of penicillin. When cells were confluent, 
a double transfection was performed, using Opti-MEM as medium and Lipofectamine 2000 as 
transfection reagent. The first transfection was done with 4 µg of DNA (human A53T or mouse 
αS, both in vector pcDNA3.1) and 10 µL of Lipofectamine in a total volume of 500 µL of Opti-
MEM. After 24 h, cells medium was removed and a second transfection was performed with no 
material (negative control) or 2 µL of 500 nM antisense oligonucleotide (Scramble, ASO 1, ASO 
2 or ASO 3) and 10 µL of Lipofectamine in a total volume of 500 µL of Opti-MEM. 
 
Cell lysis and western blot analysis 
24 hours after the second transfection, cells were washed twice with PBS and lysed on ice in 200 
µL lysis buffer (1X PBS, 1% Tx-100, 1% SDS) with proteases and phosphatases inhibitors. Lysed 
cells were scraped onto 6-well culture plates and then collected in tubes. The total lysates 
collected were sonicated and boiled for 5 min at 95°C. Protein amount was determined with BCA. 
Western blot analysis was performed as previously described for tissues in this section. 
 
Mice treatment 
10 weeks old Tg mice received biotinylated ASO 2 (50 µg per day) or the same volume of PBS as 
control, via rectal administration or through osmotic pumps (ALZET, CA, USA). Rectal 
administration was performed on the mouse under anesthesia with oxygen and isofluorane, using 
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a small-gauge soft flexible tubing and a 0.5 mL syringe. The tubing was gently inserted through 
the anus for  ̴ 3 cm and 300 µL of solution were administred. As for the osmotic pumps, one pump 
was inserted for each mouse under anesthesia with oxygen and isofluorane, after surgically 
opening the abdomen, and positioned with its flow-moderator next to the distal colon. The mouse 
was then stiched up with surgical clips and left undisturbed in its originary cage. For a 
preliminary evaluation of the ASO distribution, Tg mice received one single 50 µg dose of ASO 
rectally and were sacrificed after 6 h, or 150 µg of ASO distributed in 3 days of continuous 
diffusion by osmotic pump, model 1003D (100 µL). For the actual experiment, rectal 
administration was repeated every day for 7 days, and the pump model 2001 (200 µL) was used 
for 7 days of continuous delivery (Fig.2.4). Before and at the end of the 7 days treatment, Tg mice 
were assessed for WGTT; at the end of both experiments, the mice were sacrificed for tissues 
collection. 
 
Fig.2.4 Experimental design for mice treatment. 10 weeks old Tg mice received as treatment ASO 2 in 
the dose of 50 µg per day, or the same volume of PBS as control. The administration was rectal or through 
osmotic pump. For the rectal group, 7 administrations were performed for 7 consecutive days (day 1 to day 
7). For the pump group, the implant was done on day 1, and the drug or vehicle diffusion was constant from 




All values are expressed as the mean ± SEM. Differences between means were evaluated by two-
way ANOVA, followed by Fisher’s LSD post-hoc test, or by one-way ANOVA in case the 





Constipation in PrP A53T αS Tg mice is already present at 3 months of age in 
absence of overt motor dysfunction and accumulation of αS CNS inclusions 
To determine whether PrP A53T αS Tg mice can be used as a suitable model to study constipation 
as it occurs in the prodromal phase of PD, we first analyzed motor deficit and correlated 
accumulation of αS-positive inclusions in the CNS, two typical features of this model, in young 
and adult presymptomatic mice, to exclude that subtle changes in the αS-driven phenotype were 
already present at young age before the appearance of full-blown motor dysfunctions. In the 
presymptomatic stage these mice did not show any gross motor abnormalities, maintained normal 
gait (Fig.3.1a, b, c, d) and balance (Lee et al., 2002b), while presence of phosphorylated (S129) 
αS inclusions in medulla (Fig.3.1g, h, i, j) and spinal cord (Colla et al., 2018) of sick Tg animals 
but not 9 months old presymptomatic (Fig.3.1e, f) was found, confirming that the appearance of 
αS-driven pathology in the CNS is closely linked and concomitant with onset of motor 
dysfunction and neurodegeneration. Additionally, presymptomatic mice up to 9 months of age do 
not show signs of neuronal dysfunction in the CNS including the appearance of ER stress 
markers, ER stress-induced cell death and accumulation of microsomes-associated and 





Fig.3.1 αS Tg presymptomatic mice do 
not display motor deficits nor αS 
pathology in the CNS. αS Tg mice were 
evaluated for αS-driven pathology and 
motor abnormalities. During the gait test 
presymptomatic 3 and 6 months old 
mice were allowed to walk on a white 
paper strip with painted paws and stance 
length, sway distance and stride length 
were measured. The walking pattern in 3 
and 6 months old Tg and nTg mice 
remained unchanged. a) Representative 
walking patterns of a presymptomatic 6 
months Tg and its nTg littermate do not 
show differences in stride and stance 
length and sway distance. b, c, d) Graphs 
of gait parameters analyzed in 3 and 6 
months old mice. Values on graphs are 
expressed as raw data and are given as 
the mean ± SEM (n=5/10 per group), 
two-way ANOVA followed by Fischer’s 
LSD test. e, f, g, h, i, j) 
Immunofluorescence analysis of medulla 
in 9 months presymptomatic (e, f) or 
sick (g, h, i, j) αS Tg mice stained with 
pS129-αS antibody (f, h, i, j) or DAPI (e, 
g). Phosphorylated pathological αS was 
found only in sick Tg mice after the 
onset of neurodegeneration, indicating 
the lack of αS-driven pathology in the CNS of adult presymptomatic animals. i, j) Magnifications of image 
h for lateral reticular nucleus, magnocellular part (i) and nucleus of the solitary tract (j). Images were 
acquired with Nikon epifluorescence microscope, objective 4x, scale bar = 100 μm (e, f, g, h) or objective 






Once confirmed that αS Tg mice are free of αS pathology in the CNS at least until 9 months of 
age, we started to analyze GI functionality by evaluating the WGTT, that is the time it takes for an 
edible dye to travel through the GI tract and to be excreted. At 3 months of age, the average 
transit time was 5.919 ± 0.2768 h for αS Tg mice and 4.117 ± 0.2751 h for nTg littermates, 
indicating that αS Tg mice had a transit delay of almost 2 h when compared to controls 
(p<0.0001). This difference increased over time, reaching a plateau at 6 months of age (the 
average transit time was 7.680 ± 0.242 h for αS Tg mice and 4.555 ± 0.174 h for nTg mice, 
p<0.0001), with a delay of more than 3 h compared to nTg littermates that was maintained later 
with aging (Fig. 3.2a). To see whether constipation was present before 3 months of age or it could 
be based on gender differences, we assessed this parameter also in 1 and 2 months old mice and 
we analyzed males and females data separately. In both gender groups, no significant differences 
between Tgs and nTgs were observed for WGTT until 3 months of age. Tg females displayed a 
slower average transit compared to Tg males, of about 45 min at 2 months and of about 1 h from 
6 months (Fig.3.2b, c). Overall, despite these differences, WGTT trends resulted comparable in 
the two Tg groups. Since such a slowed transit time can affect the amount of pellets expelled, we 
measured the stool total weight and water content in young and adult mice. To our surprise, stool 
weight recorded in 1 h period (Fig.3.3a) and related water content (Fig.3.3c) remained unchanged 
between Tgs and nTgs at all time points considered. Likewise, mice growth measured through 
body weight and food intake was comparable between the two groups up to 9 months of age. No 
food malabsorption, episodes of vomit or diarrhea, nor hyperglycemia were observed (Fig.3.3d, e, 
f), suggesting that the marked delay in transit time was more likely to be related to GI dysmotility 
rather than digestive abnormality. In agreement with this, when stool output frequency for each 
single animal was measured in 1 h trial, αS Tgs at 3 months of age showed already a 40% 
reduction in stool number (2.243 ± 0.221 for αS Tgs versus 3.670 ± 0.346 for nTgs, p 
value=0.00048) and a correlated 1.4-fold increase in stool length (7.864 ± 0.477 for αS Tgs versus 
5.599 ± 0.242 for nTgs, (p<0.0001) (Fig. 3.2d, e, f). This difference was maintained in 
presymptomatic 6 months old mice but not at 9 months, suggesting that at 9 months other 
pathological processes might have affected directly or indirectly GI functionality in Tg animals 
and some mice might have been already committed to develop shortly αS-driven neuronal 
pathology in the brain. In line with this hypothesis, from 9 months of age αS Tgs showed a slight 
reduction in body weight and food intake consistent with changes in feeding behavior typical of 
motor symptoms onset (Fig.3.3d, e). Thus, young Tg mice showed signs of constipation and GI 
abnormalities in presymptomatic conditions that largely anticipate the appearance of αS pathology 
in the CNS. In addition, the drastic increase in WGTT in young αS Tg mice did not translate into 
a decrease of total amount of stools but rather affected the number and length of single pellets 





Fig.3.2 GI dysfunction in presymptomatic αS Tg mice is present starting from 3 months of age. GI 
functionality was evaluated through behavioral tests in presymptomatic 1, 2, 3, 6, 9 and 12 (if healthy) 
months old αS Tg mice and nTg littermates. Each trial was performed 1 to 3 times per animal on non 
consecutive days. Groups comprised 20-30 mice with similar presence of females and males. GI behavioral 
analysis showed significant constipation in young and adult Tg animals and nTg age-matched littermates. a, 
b, c) WGTT was recorded as the time for a non absorbable dye to travel through the GI tract. a) The transit 
time is increased in presymptomatic αS Tg mice versus controls starting from 3 months and exacerbates 
with age, reaching an average 3 h 12 min delay in Tg animals by 6 months of age. b, c) A comparable result 
was obtained when considering males and females separately. Notably, Tg females have a slower transit 
time compared to males, starting from 2 months of age. d, e, f) Presymptomatic αS Tg mice excreted a 
reduced number of stools but with an increased length compared to controls already at 3 months. d) 
Representative image of stools collected in 1 h trial from a 6 month old αS Tg mouse and littermate. 
Notably, pellets from young Tg mice are longer but less abundant. e, f) Pellets from each mouse were 
collected in 1 h trail. Stools from Tg mice were consistently longer and less abundant compared to controls. 
Values on graphs are expressed as raw data and are given as the mean ± SEM (n=20-30 per group). * 





Fig.3.3 GI dysfunction in presymptomatic Tg mice. Stool weight, feeding behavior, body growth and 
glycemic levels are not affected in presymptomatic αS Tg mice. Additional parameters related to GI 
functionality were evaluated through behavioral tests in presymptomatic αS Tg mice and nTg littermates. 
Each trial was performed 1 to 3 times per animal on non consecutive days. Groups comprised 20-30 mice 
for stool tests and body weight, or 10 mice for glycemic tests, with similar presence of males and females. 
a, b, c) Pellets from each mouse were weighted for total stool weight, then let dry o/n at 65 °C and weighted 
again to measure dry stool weight and water content. No difference in total (a), dry stool weight (b) nor 
water content (c) of pellets was found between Tgs and controls at any time point. d) Food intake was 
measured in a 24 h trial. No significant difference was found between the two groups in the amount of chow 
ingested until 9 months of age, indicating that GI dysfunction was not due to erratic food consumption. e) 
Body weight of the animals remained comparable between the two groups until 12 months of age, a time in 
which surviving Tg mice may have been already committed to develop shortly the full motor phenotype. 
Maybe for a compensation at this time point close to central pathology, 12 months old Tgs appear to 
increase their food intake compared to controls (d). f) Glycemic levels were measured under fasted and fed 
conditions. No variations were noticed between the two groups, nor diabetes-like signs were present at any 
time. Values on graphs are expressed as raw data and are given as the mean ± SEM. * p<0.05, two-way 





Presymptomatic αS Tg mice show a reduced electrically evoked motor response of 
the colonic muscle layers from 3 months of age 
Since constipation is correlated with a deficit in bowel motility, we recorded colonic and ileal 
contractility of longitudinal and circular muscles in young and adult αS Tg mice. Electrical 
stimulation of the colon from αS Tg mice showed a clear reduction in the magnitude of motor 
response of both muscle layers compared to controls, that was already present in 3 months old 
Tgs. In particular, the circular muscle seemed more affected since its response to stimulation was 
increasingly reduced with aging in αS Tg mice (Fig.3.4a). By contrast, in control animals, 
electrically evoked contractions showed consistently similar patterns of magnitude at all ages 
analyzed. To establish whether the reduced motor response in the colon of αS Tg animals was due 
to an impairment of a specific system within the ENS, we recorded the contractile response after 
selective stimulation of the nitrergic, cholinergic or tachykinergic system, pharmacologically 
isolated by using specific inhibitors (Fig.3.4b, c, d). Remarkably, only the excitatory cholinergic 
component was consistently impaired in Tgs compared to age-matched littermates at all ages 
analyzed, as shown by the decrease of the electrically evoked motor response, whilst the other 
systems appeared not affected. This deficit in cholinergic transmission indicates that the increase 
in WGTT with concomitant alteration in stool formation is mainly due to a decrease in colon 
muscle contraction, rather than a dysfunction in muscle relaxation, which is mainly modulated in 
mice by the nitrergic system (Mang et al., 2002). Furthermore, in order to understand whether this 
deficit was myogenic or neurogenic, we evoked colonic contractions by direct pharmacological 
activation of muscarinic receptors located on smooth muscle cells, by using tetrodotoxin and 
carbachol (Fig.3.4e). Interestingly, in this case the motor response was comparable between Tgs 
and controls at all ages analyzed, indicating that the observed colonic dysmotility of Tg animals 
was mainly related to a deficit in the neural component. In addition, since WGTT is a measure of 
the transit time for the whole GI tract, electrical stimulation of ileal preparations from 
presymptomatic mice at 3 and 12 months was performed (Fig.3.4f). To our surprise, motor 
response in the ileum was comparable between Tg and nTg animals for both time points, 
indicating that the deficit in contraction seen in young Tg mice was specific for the colon. Thus, 
the reduced contractility of the colon in presymptomatic mice, due to an altered cholinergic 








Fig.3.4 Colonic contractile activity is impaired in presymptomatic αS Tg mice from 3 months of age. 
Electrical stimulation (ES) of intestinal tissues shows a reduced response of longitudinal (L) and circular 
(C) smooth muscles in Tg mice already at 3 months, in the colon but not the ileum. The reduced contraction 
was mainly due to a decreased cholinergic transmission and exacerbated with age. Recordings were 
performed in αS Tg mice and nTg littermate controls in colon (a, b, c, d, e) and ileum (f). a, f) Effect of ES 
(↑=ES, 10 Hz) on the contractile activity of colonic (a) or ileal (f) preparations maintained in standard 
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Krebs solution in order to register the overall response. b) Effect of selective ES (↑=ES, 10 Hz) of the 
inhibitory nitrergic pathway on the activity of colonic muscles in order to record nitrergic-induced response. 
Colonic preparations were maintained in Krebs solution containing guanethidine, L-732,138, GR159897, 
SB218795  and atropine. c) Effect of selective ES (↑=ES, 10 Hz) of the excitatory cholinergic system on the 
activity of colonic muscles in order to record cholinergic-induced contractions. Colonic sections were 
maintained in Krebs solution containing L-NAME, guanethidine, L-732,138, GR159897, and SB218795. d) 
Effect of selective ES (↑=ES, 10 Hz) of the excitatory tachykinergic pathway on the activity of colonic 
muscles to record NK1-mediated tachykinergic contractions. Colonic preparations were maintained in 
Krebs solution containing L-NAME, guanethidine, GR159897, SB218795, atropine. e) Effects of carbachol 
(↑=Cch; 10 µM) stimulation on the activity of colonic preparations in order to record the myogenic 
response in absence of neurogenic stimulation. Colonic preparations were maintained in Krebs solution 
containing tetrodotoxin. Tracings in the inset on the top of each panel display the contractile responses to 
ES, as raw data. Values on graphs are expressed as % relative to controls and are given as the mean ± SEM 
(n=8 per group). * p<0.05; **** p<0.0001, two-way ANOVA followed by Fischer’s LSD test. 
 
Accumulation of αS soluble and insoluble HMW species in the colon increases over 
time in presymptomatic αS Tg mice 
In order to investigate whether the expression of αS could be related to the GI deficits that we 
observed, we performed immunoblot analysis on the intestine of young and diseased animals to 
check for peripheral distribution of αS. The whole length of the intestine was examined from the 
pylorus to the rectum, divided into six segments corresponding to duodenum, jejunum, proximal 
and distal ileum, proximal colon and distal colon. Western blot assays showed that αS monomer 
was present at low level in all fractions analyzed, with the exception of the colon where αS 
transgene expression reached a ~60-fold increase, compared to the small intestine, in 
presymptomatic 3 months old Tg animals (Fig.3.5). Very interestingly, when NP-40 insoluble 
fraction was run, 3 months old presymptomatic αS Tg mice already showed accumulation in the 
colon (mainly in the distal segment) of aggregated HMW species of αS. In diseased mice, after 
CNS neuronal degeneration onset, αS distribution was similar to that found in 3 months old mice, 
although the level of HMW αS was higher, suggesting a possible increase in αS inclusions 











Fig.3.5 Intestinal αS distribution in presymptomatic and diseased αS Tg mice. Distribution of αS 
transgene expression was assessed in young presymptomatic (3 months old) and diseased Tg mice. Fresh 
mouse intestinal tract was divided into six segments corresponding to anatomical distinct areas: duodenum 
(D), jejunum (J), proximal ileum (PI), distal ileum (DI), proximal colon (PC), distal colon (DC). NP-40 
soluble (N-SOL) and insoluble (N-PEL) fractions were loaded on a SDS-PAGE and blotted for Syn1 and α-
Tubulin or GAPDH antibodies. αS expression was more abundant in the colon of both 3 months old 
presymptomatic (a) and sick αS Tg (d) mice, compared to the small intestine (p<0.0001) or nTg age-
matched littermates lysates, although it was present at minimal level in all fractions examined in Tg mice. 
Notably, insoluble and more surprisingly soluble fraction contained HMW αS species. FL αS, full length 
αS, ΔC αS, truncated αS. b, c, e, f) Relative density of αS monomer in soluble (b, e) or insoluble (c, f) 
fractions. Values on graphs are expressed as % relative to nTg and are given as the mean ± SEM (n=3-4 per 
group). * p<0.05; **** p<0.0001, two-way ANOVA followed by Fischer’s LSD test. 
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In fact, when the proximal and distal colon from different ages were specifically analyzed for αS 
aggregates, we found an increased accumulation of insoluble and aggregated species of αS over 
time for both segments, although the distal colon appeared more affected, that peaked at 6 months 
and remained stable at later time points (Fig.3.5d, e, f) whereas αS monomer level did not change 
(Fig.3.6). 
 
Fig.3.6 Distribution of αS monomer in the colon of 
presymptomatic Tg mice. Relative density of αS 
monomer in the proximal (P) and distal (D) colon of 
Tg mice and age-matched controls at various age 
shows that αS monomer level does not change with 
age. Quantitative analysis of immunoblots of soluble 
(a) and insoluble (b) fractions presented in Fig.3.7. FL 
αS, full length αS. Values on graphs are expressed as 
% relative to nTg and are given as the mean ± SEM 
(n=3/4 per group). **** p<0.0001; two-way ANOVA 
followed by Fischer’s LSD test. 
 
Notably, also the soluble fraction of the proximal and distal colon contained soluble HMW 
oligomers of αS, the amount of which increased with aging and paralleled the trend seen for αS 
insoluble aggregates (Fig.3.5a, b, c). In addition, phosphorylated αS at S129 was also detected in 
both insoluble and, more surprisingly, soluble fractions of the colon (Fig.3.5c, f), a unique 
condition of the ENS, since phospho-αS species accumulate in the CNS of this line only after 
neurodegeneration onset and mainly in non ionic detergent-insoluble pellet (Fig.3.1) (Colla et al., 
2012a, 2012b, 2018). Thus, accumulation of phosphorylated αS inclusions in the colon of αS Tg 
mice largely precedes brain neuropathology, mimicking behavior and physiology data. Moreover, 
soluble αS is already phosphorylated at 3 months of age and forms stable, but still soluble, HMW 
oligomers, suggesting that the pathobiology of αS may differ between the CNS and the ENS. 
It is also interesting to notice that truncated αS is present at all ages in proximal and distal colon. 
Although we have not focused on this specific aspect yet, it may be possible that two different 
truncated forms are present in proximal and distal colon respectively, as it appears from the blots 
at least at 3 and 9 months of age for Tg presymptomatic mice. It would be interesting to further 
characterize this issue and be able to compare the truncation pattern in the ENS of Tg mice with 
the CNS data published from our group (Li et al., 2005; Colla et al., 2018). Based on our 
observations, we demonstrated that the accumulation of specific αS truncated species in the CNS 
varies bewtween presymptomatic and diseased Tg mice, when analyzing different subcellular 




Fig.3.7 αS soluble and insoluble HMW species in the colon increase with age in presymptomatic mice. 
Time course analysis of soluble and insoluble fractions obtained from the proximal (P) and distal (D) colon 
of presymptomatic Tg mice at different age shows an increase in the accumulation of αS HMW species. 
NP-40 soluble (a) and insoluble (d) lysates of proximal and distal colon were isolated from presymptomatic 
Tg mice and nTg littermates at different age, run on a SDS-PAGE and blotted with Syn1, pS129-αS and 
GAPDH antibodies. Soluble and insoluble phospho-αS HMW species were already abundantly present in 
Tg mice at 3 months of age and their level exacerbated with age, reaching a plateau at 6 months. The distal 
colon appears to be the intestinal region with the highest presence of αS HMW species. b, c, e, f) Graphs 
showing relative density of HMW αS (b, e) or phospho-αS (c, f) in all fractions analyzed. Values on graphs 
are expressed as % relative to nTg and are given as the mean ± SEM (n=3-4 per group). * p<0.05; ** 
p<0.01; *** p<0.001; **** p<0.0001, # p<0.05; ## p<0.01; ### p<0.001; #### p<0.0001, where * refers to 
comparisons between Tgs and their nTg age-matched controls, while # refers to comparisons between distal 
and proximal colon of Tgs; two-way ANOVA followed by Fischer’s LSD test. 
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By using a specific antibody that can detect oxidated and aggregated αS forms in dot blot but not 
western blot assays (due to the necessity of not denaturate such aggregates), we were able to 
further characterize the nature of the HMW species found in the insoluble fraction of colon 
lysates. With a similar trend of the previous time course data, the dot blot performed on proximal 
and distal colon of Tg and control mice at all time points, confirmed an accumulation of 
aggregated species in Tgs in both segments of the colon already at 3 months of age, with higher 
levels in the distal part and a peak at 6 months (Fig.3.8) 
 
 
Fig.3.8 Time course of αS insoluble 
oligomers in the colon of 
presymptomatic and diseased Tg 
mice. a) NP-40 insoluble fractions from 
proximal (PC) and distal (DC) segments 
of the colon of presymptomatic and sick 
αS Tg mice and controls were blotted 
with an antibody specific for oxidated 
and aggregated αS, Syn303. b) Dot blot 
values in the graph are expressed as % 
of age-matched nTg mice and given as 
the mean ± SEM (n=3 per group). * 






Pathological αS in presymptomatic and diseased αS Tg mice is found in ChAT-
positive and TH-positive enteric neurons of the colon 
In order to further investigate the distribution of pathological αS in the colon of Tg mice, we 
performed immunofluorescence analysis on frozen sections of the distal colon in 3 months old 
presymptomatic and sick Tg mice. Colocalization with β-3-Tubulin, a pan-neuronal marker, 
showed that αS aggregates were present only in neurons, mainly in the soma, of both myenteric 
and submucosal plexi of the ENS of Tg animals (Fig.3.9a, b, c). A further double immunostaining 
was carried out with specific neuronal type markers to assess whether αS was associated with 
specific neuronal populations. αS was found in ChAT-positive neurons (Fig.3.9e, f) and in TH-
positive neurons (Fig.3.9h, i) of both enteric plexi. Interestingly, not all ChAT-positive and TH-
positive neurons stained for αS, which was concomitantly seen in other neuronal populations. 
This suggests a dynamic progression in the spreading and/or accumulation of toxic αS in the ENS. 
Thus, accumulation of αS aggregates in colonic enteric neurons in both plexi is associated with 
the onset of constipation and GI transit abnormalities that manifest in αS Tg mice in 
presymptomatic conditions without overt neurodegeneration in the CNS.  
 
 
Fig.3.9 Accumulation of pathological αS in enteric neurons of presymptomatic and sick αS Tg mice. 
Immunocolocalization with neuronal markers shows accumulation of αS toxic species only in enteric 
neurons, including ChAT-positive and TH-positive types, in both the submucosal and myenteric plexi in Tg 
mice but not in controls. Distal colon frozen sections from 3 months old presymptomatic (b, e, h) and sick 
αS Tgs (c, f, i) and nTg littermates (a, d, g) were stained with LB509 and β-3-Tubulin (a, b, c); ChAT and 
pS129-αS (d, e, f); Syn204 and TH  (g, h, i). Sections were counterstained with DAPI. Notably, within the 
same section and concurrently with double labeled neurons (full arrow heads), we found healthy neurons 
without accumulation of toxic αS (empty arrow heads) or neurons with accumulation of toxic αS that 
belonged to other neuronal populations beyond the ChAT-positive or TH-positive (*), suggesting that 
different enteric neurons may be distinctively susceptible to αS spreading. Images were acquired with Leica 








Antisense oligonucleotide treatment 
 
After a detailed characterization of PrP A53T αS Tg mice line G2-3 from an enteric point of view 
and with a peculiar focus on the prodromal phase, we proceeded our research toward a disease 
modifying direction, through therapeutic intervention. Our strategy was to use an ASO directed to 
the periphery, in presymptomatic 10 weeks old Tg mice. 
ASOs are small, single-stranded sequences of nucleic acids, between 8 to 50 nucleotides in 
length, able to bind to a complementary target mRNA through standard Watson-Crick base 
pairing. This specific matching results in the alteration of the original function of the target RNA, 
through different mechanisms, which largely depend on the chemical structure of the ASO itself. 
One frequent mechanism is the recruitment of RNase H, an endogenous enzyme that recognizes 
RNA/DNA heteroduplexes and degrades the target RNA after its binding with the ASO. The 
destruction of the mRNA prevents its translation into protein, yielding a decrease of the intended 
target. This approach is useful for pathologies characterized by the accumulation of specific 
proteins, such as αS in PD, and many other neurodegenerative disorders (DeVos and Miller, 
2013). In order to be able to recruit RNAse H, the ASO needs to have a phosphorothioate (PS) 
backbone, a very common modification which consists in replacing the oxygen atom in the 
phosphodiester linkage with a sulfur atom. Besides allowing the RNAse H mechanism, the PS 
backbone improves the ASO pharmacokinetics, by increasing its resistance against nucleases 
degradation and its binding to plasma proteins, which ultimately lead to a higher concentration 
and a more efficient cellular uptake (Schoch and Miller, 2017). Another largely used modification 
involves the sugar moiety at the position 2’ and consists in the addition of a 2’-O-methoxyethyl 
(MOE) group. This leads to a higher binding affinity of the ASO to the target RNA and it helps 
overcoming some disadvantageous immunostimolatory properties of the PS backbone, thus 
reducing the ASO toxicity (Evers et al., 2015). However, ASOs made of fully modified 2’-sugar 
moieties lose the ability of recruiting RNAse H, and this is why in order to exploit the advantages 
of both modifications it is necessary to further manipulate the sequence with a gapmer design. A 
gapmer ASO has a central region with unmodified sugars, flanked by two shorter regions with 
modified sugars. It is important to point out that a gapmer 2’-MOE PS ASO was the first to be 
used in a clinical trial for a neurodegenerative disease, with a positive outcome in terms of safety 






Fig.3.10 Schematic representation of structure and mechanism of action of a gapmer 2’MOE PS 
ASO. a) Panel depicting the two most common modifications for ASOs at the backbone and 2’sugar ring, 
which are the phosphorothioate (PS) modification (in yellow) and the 2’-O-Methoxyethyl (MOE) 
modification (in blue) respectively. b) Example of a 20-mer PS ASO (PS group in red) with a gapmer 
design, consisting in a central region of 10 nucleotides with unmodified sugars, flanked by two regions of 5 
nucleotides each, with modified sugars (MOD, in blue). The gapmer design allows a PS 2’-MOE modified 
ASO to maintain its ability of RNAse H recruitment, otherwise lost with a full 2’-MOE modification for its 
entire length. This RNAse H mechanism of action (c) is possible thanks to the specific matching of the 
ASO to a target mRNA and results in the mRNA degradation. This approach is particularly useful for 
neurodegenerative diseases, in which reducing the levels of a specific toxic protein would contrast the 
development of the pathology (DeVos and Miller, 2013). 
 
ASO treatment reduces selectively human A53T αS expression in SH-SY5Y cells 
In line with this strategy, we designed three gapmer 2’-MOE PS ASOs directed against αS and 
one scramble ASO with a random non matching sequence to be used as negative control. ASO 1 
and ASO 2 matched with the human A53T αS, whilst ASO 3 matched with both human A53T and 
murine αS. In a first experiment we tested the efficiency of all three ASOs against human A53T 
αS. Cells were transfected first with human A53T αS and then with the ASO to be evaluated. 
Immunoblots of cell lysates showed comparable levels of inhibition in αS expression (Fig.3.11). 
Because of this, we chose ASO 2 for further characterization. In order to confirm that ASO 2 does 
not inhibit murine αS expression, a critical issue to be evaluated in view of a treatment in mice, 
we repeated the experiment transfecting SH-SY5Y cells with human A53T or mouse αS. As 
expected, this ASO reduced significantly human A53T αS but not mouse αS levels (Fig.3.12). 






Fig.3.11 ASOs against αS tested in SH-
SY5Y cells expressing A53T αS. a) 
Expression of αS measured in SH-SY5Y 
cell line lisates after a first transfection with 
A53T human Tg αS and second transfection 
with no material (negative control) or ASO 
scramble (S, control), ASO 1, 2, 3. b) 
Quantification of αS/GAPDH levels for 
















Fig.3.12 ASO 2 tested in SH-SY5Y cells expressing human Tg A53T or mouse αS. a) Expression of αS 
measured in SH-SY5Y cell line lisates after a first transfection with A53T human Tg or mouse αS, and 
second transfection with no material (-, negative control), antisense oligonucleotides scramble (S, control) 
or ASO 2, in triplicates. b) Quantification of αS/GAPDH levels for A53T and mouse αS. Values on graphs 
are expressed as % relative to negative control and are given as the mean ± SEM (n=3 per group). *** 





ASO is uptaken at the colon following rectal or osmotic pump delivery in mice 
Before testing ASO 2 inhibitory effect in vivo, we performed a preliminary experiment to verify 
how its distribution takes place in the colon of mice. In order to make the ASO detectable in 
tissues an additional 3’ biotin TEG was added to the original ASO 2 sequence. Since we 
demonstrated that αS pathology in this mouse model affects both submucosal and myenteric 
neurons of the colon, we decided to use two different delivery routes, rectal or osmotic pumps, in 
order to reach both plexi. Rectal administration is less expensive, but probably more stressful for 
the animal, as it requires to be repeated several times by the operator, and maybe for this reason it 
was also related to a higher mortality. Osmotic pumps implant requires one single surgical 
intervention, which is more invasive but less problematic for the mouse in a long-term 
perspective. None of the implanted mice died following the procedure, but did so for the rectal 
route during the second experiment. Although rectal administration might seem easier in terms of 
expertise, both techniques require a good command of surgical skills and animal handling. To 
check the ASO distribution, Tg mice received ASO 2 or PBS for 3 days in the case of osmotic 
pump implant or in one single dose in the case of the rectal route. Mice were sacrificed after 3 
days of diffusion (pumps) or 6 h after administration (rectal) and serial frozen sections of the 
colon were stained using a Streptavidin antibody that recognizes the 3’ biotin TEG cap in the 
ASO 2 sequence. Despite detecting the ASO in tissues was not simple, as some of the amount was 
probably degraded or reached undesired areas, ASO specific immunofluorescent signal was 
detected in samples from both administration routes in proximity of neuronal and non neuronal 
cell types (Fig.3.13). 
 
 
Fig.3.13 ASO distribution after colonic administration in presymptomatic αS Tg mice. 
Immunocolocalization with neuronal markers shows the presence of biotinylated ASO in the colon of 
ASO treated mice but not in PBS treated controls. Frozen sections of distal colon mounted according to 
the “Swiss roll” procedure from presymptomatic 3 months old Tgs were stained with Streptavidin for 
detecting biotinylated ASO, and SV2 together with NF200 for peripheral neurons. Sections were 
counterstained with DAPI. The mice received the treatment rectally (a, b, e) or through osmotic pumps (c, 
d, f), containing ASO (b, d, e, f) or PBS as control (a, c). The tissues were collected 6 h after one rectal 
administration (a, b, e) or 3 days after pumps implant (c, d, f). The images below (e, f) represent a 
magnification of b, d merges respectively, from the selected area. As expected, no Streptavidin-positive 
signal was detected in PBS treated mice (a, c), whilst it was found in ASO treated mice (b, d, e, f). In both 
rectal (b, e) and pump (d, f) routes group, the ASO signal was detected in proximity of neurons (full arrow 
heads) and in proximity of other enteric cell types (empty arrow heads). Images were acquired with ZEISS 























ASO treatment targeting the colon rescues the impaired transit time in young αS Tg 
mice 
Once confirmed the uptake of ASO at the level of the desired target, we performed a treatment of 
young Tg mice for 7 days, with a dose of 50 µg per animal per day, distributed in 7 
administrations for the rectal group every day at the same time, or through a continuous diffusion 
following the implant for the osmotic pump group. The ideal time to start the ASO treatment in 
our model would be before the onset of constipation, that means well before before 3 months of 
age. Because of the limitation in the use of osmotic pumps in young animals, which depends on 
body size, we chose to initiate the treatment at 10 weeks and to use an all-male group of mice for 
osmotic pumps, due to their larger size compared to females. Additionally, during the practice for 
rectal administration, females resulted easier to manipulate compared to males. Thus, we used an 
all-female group for this route. Tg mice were analyzed for WGTT before (Day 0) and after 
receiving the ASO for 7 days (Day 7). All mice were then sacrificed and the expression of total 
αS in the colon was assessed. At the end of a 7 days treatment, Tg mice which received the ASO 
displayed a significant reduction in their WGTT compared to controls which received PBS only 
and compared to the time point before starting the treatment, for both routes of administration. 
Specifically, within the rectal group the average transit time of Tg mice was 6.267 ± 0.081 h at 
Day 0 and 4.267 ± 0.185 h at Day 7 (p<0.0001), meaning 2 h of decrease, whereas for the pumps 
group it was 4.933 ± 0.376 h at time point 0 and 3.528 ± 0.2037 h after 7 days of ASO treatment 
(p=0.0004), which is about 1.5 h of decrease. The difference in the baseline of WGTT at Day 0 
between females and males was known before starting the analysis as we have previously 
discussed and showed in Fig.3.2.  
Moreover, compared to the respective PBS group at Day 7, ASO treatment resulted in a 
significant decrease in transit time for both routes of administration, with a WGTT of 4.266 ± 
0.185 h vs 5.083 ± 0.417 h for the rectal group (p=0.0362) and 3.527 ± 0.204 h vs 4.418 ± 0.108 h 
for the pumps group (p=0.0495), which is about 50 min of decrease for both cases. To notice, for 
rectal administration, we observed a reduction in WGTT at Day 7 also for PBS treated Tg mice, 
although less pronounced with respect to the ASO treated group. We believe this was the result of 
repeated rectal administrations, consisting every time in 300 µL of liquid entering the distal colon, 
thus stimulating bowel movements for evacuation. For future experiments, one way to avoid this 






Fig.3.14 WGTT in young Tg mice ameliorated after 7 days of ASO treatment. WGTT was measured 
before starting the treatment (Day 0) and after 7 days of ASO treatment (Day 7), which was administred 
rectally (a) or through osmotic pumps (b). In both cases, 10 weeks old Tg mice received 50 µg of ASO per 
day or PBS for the control groups. Values on graphs are expressed as raw data and are given as the mean ± 
SEM (n=3-6 per group) . * p<0.05; *** p<0.001; # p<0.05, where * refers to comparisons between the 
same group at Day 7 versus Day 0, while # refers to comparisons between PBS and ASO group at Day 7; 
two-way ANOVA followed by Fischer’s LSD test. 
 
After WGTT measurement, mice were sacrificed and tissues were collected for further analysis. 
In order to investigate whether the ASO treatment reduced αS protein expression in the colon of 
Tg mice, in correlation with the changes observed for transit time, we performed immunoblot 
analysis on proximal and distal colon and checked for αS levels. Western blot assay showed that 
total αS level was reduced, although not significantly, of about 35% and 50% in rectally and 
pumps ASO treated mice compared to PBS controls only in the distal colon, but remained 
unchanged in the proximal colon (Fig.3.15). 
Thus, this reduction in αS protein level in the colon after ASO treatment was sufficient to improve 
constipation in young Tg mice. We believe that repeating the experiment with a more congruous 
number of animals, increasing the ASO dosage and/or prolonging the treatment to 2 weeks or 






Fig.3.15 αS levels in the colon of young Tg mice after 7 days of ASO treatment. a, b) Immunoblot for 
αS in NP-40 soluble lisates from proximal colon (PC) and distal colon (DC) of Tg mice treated with PBS or 
ASO, rectally (a) or through osmotic pumps (b), for 7 days. c, d) Quantification of FL αS/GAPDH levels 
for rectal (c) or pumps (d) group. Although not significant, there is a reduction of αS monomer in both 
rectal (a, c) and pumps (b, d) treated mice in the distal colon and no change in the proximal colon. Values 








This research demonstrates that the PrP A53T αS Tg mice line G2-3 can be an extremely valuable 
model and to the best of our knowledge the only one at present, for studying constipation as it 
occurs in the prodromal phase of PD, meaning in absence of overt motor abnormalities and CNS 
neurodegeneration (Rota et al., 2019). This mouse model developed in 2002 (Lee et al., 2002b) is 
defined as a model of α-synucleinopathy, since it shows a non significant decrease of DA in the 
SN and no signs of dopaminergic neurodegeneration in the SN, two pathophysiological elements 
relevant for PD definition, probably because the central pathology develops so fast that the animal 
dies before the expected neurodegenerative process takes place. Concomitant with typical motor 
dysfunctions upon which diagnosis is still mainly made, PD patients experience a plethora of non 
motor symptoms affecting both the CNS and the PNS (Schapira et al., 2017). Among these, GI 
symptoms and specifically constipation represent an important feature of the prodromal phase of 
the pathology, since GI abnormalities can appear even decades before the onset of motor signs 
(Cersosimo et al., 2013). The relevance of studying constipation is also attributable to the fact that 
it affects 80% of PD patients, and after being diagnosed with constipation there is almost a 3-fold 
increased risk of developing PD (Abbott et al., 2001). Nevertheless, whether there is a direct 
pathogenic correlation between GI dysfunction and PD, still remains an open issue, in part 
because of the absence of appropriate animal models able to recapitulate the chronic and 
progressive evolution of PD pathological stages. In the G2-3 line constipation and GI deficits 
precede motor dysfunction and neurodegeneration in the CNS by at least 6 months. In fact from 
an early age (3 months), when the CNS is free of αS-driven neuropathology, these mice exhibit 
significant GI dysfunction, as here documented by a strong delay in GI transit time and concurrent 
abnormalities in stool formation, which result in the production of longer but less frequent fecal 
pellets. Because of the similarities in feces consistency, food intake ration, body size and stool 
weight between Tgs and age-matched nTg littermates, which allow us to exclude issues related to 
chow malabsorption, the transit delay observed in young Tg mice could underlie dysfunctional 
bowel movements which in turn could affect the processes of formation, propagation and 
expulsion of stools. 
Consistently with this hypothesis, we found a reduced ability in contraction of longitudinal and 
circular muscle layers of the colon in young Tg mice, mainly dictated by a decreased neuronal 
transmission. In fact, while the colon muscles in Tg animals still contract normally when 
stimulated directly, the neuronal pathway supplying for such muscles was found to be deficient. 
Moreover, at 6 months of age this abnormal behavior progressively worsens, reaching a delay in 
GI transit time of more than 3 hours that was parallel to a further decrease in colon contractility, 
still in absence of any sign of CNS neurodegeneration. 
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As previously explained, the motor activity of the bowel in mice is mainly regulated by the 
cholinergic and tachykinergic systems for contraction, while the nitrergic system is the main 
regulator of gut muscle relaxation (Mang et al., 2002; Bornstein et al., 2004). When considering 
only the recruitment of postganglionic cholinergic motor neurons, electrically evoked contractions 
resulted decreased in αS Tg compared to nTg mice in both muscle layers (Fig. 3.4b). On the other 
hand, when stimulating specifically the nitrergic or the tachykinergic system, the muscle response 
was unchanged between the two groups, at all ages, confirming that GI delay in transit was 
mainly ascribable to a deficit in cholinergic-evoked muscle contractions and not to an excess of 
the relaxant response. 
In line with this view, a more accurate immunofluorescence analysis revealed toxic αS 
accumulated in enteric neurons, including ChAT-positive and TH-positive types, of both 
myenteric and submucosal plexi in presymptomatic and diseased animals. Notably, in the same 
section, not all the neurons stained for αS aggregates, suggesting that accumulation of toxic αS is 
a progressive process in which not all neuronal populations present the same degree of 
susceptibility to αS insults, especially in the gut where neuronal biodiversity is remarkable 
(Furness, 2000). Besides the renowned central DA dysfunction linked to the classical 
parkinsonian motor features (Blesa and Przedborski, 2014), other neuronal systems are affected in 
PD and have been related to both motor and non motor dysfunctions, within and outside the CNS. 
In particular, the cholinergic system has been implicated in PD progression in relation to the 
occurrence of typical motor symptoms such as postural instability and gait disturbances (Karachi 
et al., 2010), but also to non motor symptoms such as dementia and cognitive deficits (Hilker et 
al., 2005; Bohnen et al., 2006), or REM sleep behavior disorder (Kotagal et al., 2012), hyposmia 
(Versace et al., 2017) and possibly dysphagia (Lee et al., 2015), which can all arise during 
preclinical PD. Interestingly, selective accumulation of LBs in cholinergic neurons within the 
nucleus basalis of Meynert, located in the basal forebrain, has been described  to occur 
concomitantly with DA neuronal loss in the SN (Braak et al., 2003a). Also, treatment with 
cholinesterase inhibitors in PD patients appears to improve constipation and GI motility, 
supporting the importance of the cholinergic system in PD (Lepkowsky, 2018). In addition, DA 
exerts a negligible control of intestinal motility at the level of the lower digestive tract in humans 
(Bornstein et al., 2004), strongly suggesting the implication of other neurotransmitters for the 
development of GI dysfunction in PD. Hence, our observation of αS accumulating in TH-positive 
neurons has to be interpreted cautiously before considering these as DA neurons, since DA at this 
level could be a precursor for the other monoamines biosynthesis and its presence does not 
necessarly mean that the neuron in question uses DA as main neurotransmitter. 
Furthermore, in the present study we demonstrate that the bowel dysfunctions shown by 
behavioral data and electrical recordings in Tg mice are supported by a robust biochemical basis 
since immunoblot analysis of the whole intestine revealed that young presymptomatic Tg mice 
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predominantly express αS transgene only in the colon with consequent selective accumulation in 
this tract of insoluble and phosphorylated HMW aggregates already at 3 months of age. 
Remarkably, while the distribution of αS transgene expression did not change with age, including 
after the onset of central pathology, the amount of insoluble aggregates increased over time, 
reaching a peak at 6 months of age, temporally matching the increased delay in GI transit and 
reduction of gut motility, and at the same time providing a strong molecular basis for the 
behavioral and functional GI abnormalities observed. This strong correlation between αS Tg 
expression and LB-like αS aggregates in the colon with bowel dysfunction is also confirmed by 
the absence of GI dysmotility in the ileum of Tg mice, where αS expression is minimal. Therefore 
αS inclusions, neuronal deficit and dysmotility at the level of the colon in this mouse model are 
tightly connected to αS overexpression in this site and represent an early sign of αS-driven 
dysfunction, without CNS involvement. 
In PD patients, αS and LBs have been found in enteric neurons of both submucosal and myenteric 
plexi along the whole GI tract, including the colon (Böttner et al., 2012; Gelpi et al., 2014). An 
investigation led by Beach and coworkers found a rostro-caudal gradient for the accumulation of 
pS129-αS within the ENS with a higher incidence of LBs in the lower esophagus and 
submandibular gland, and lower in the colon and rectum (Beach et al., 2010). As previously 
mentioned, the involvement of the vagus nerve has been suggested as dissemination route of toxic 
αS along the gut-brain axis (Braak et al., 2003a). Nevertheless, the high incidence of aggregated 
αS in all the segments of the spinal cord suggests that other nerves may be implicated in αS 
propagation (Böttner et al., 2012; Pan-Montojo et al., 2012). In addition, several studies have 
indicated LBs presence in human colon biopsies as a possible diagnosis method for preclinical PD 
(Lebouvier et al., 2008; Pouclet et al., 2012; Shannon et al., 2012). Thus, whilst the expression of 
Tg αS at the gastric level still remains to be investigated in our mouse model, the early 
accumulation of toxic αS in the large intestine is sufficient in these mice to recapitulate distinctive 
features of GI dysfunction of human PD, making the G2-3 line an optimal paradigm to study 














Fig.4.1 Putative spreading routes of α-
synucleinopathy from the ENS to the 
brain in PD. Following a variety of 
possible exogenous and/or endogenous 
causes, αS accumulates in enteric neurons. 
This occurs in concomitance to the 
alteration of gut activity, which is 
observable by abnormal intestinal motility 
and constipation. Aggregated αS might be 
progressively released by damaged 
neurons, generating a cell-to-cell 
transmission responsible for the 
progression of the pathology, from the 
ENS toward the brain, along nuclei in 




In addition, and surprisingly, detergent-stable soluble oligomers of αS were also found in 
presymptomatic young 3 months old Tg mice and their accumulation increased over time. This 
represents a striking difference compared to the CNS, where αS soluble oligomers are only found 
at low level in adult (after 9 months) or diseased mice and are mainly associated with the 
microsomal vesicles fraction (Colla et al., 2012b, 2018). Furthermore, level of pS129-αS in the 
soluble fraction was also abundant, suggesting that αS pathobiology might differ between brain 
and gut, where modified HMW αS remains soluble for a longer period of time, instead of being 
promptly confined in insoluble inclusions. 
Notably, truncated αS was present at all ages in the colon of Tg mice and it may be possible that 
two different truncated forms are present in the proximal and distal colon. Based on other recent 
data we published for the CNS, the accumulation of specific αS truncated species varies 
bewtween presymptomatic and diseased Tg mice (Colla et al., 2018). While the toxicity remains 
to be investigated, increased solubility of αS toxic species, either phosphorylated or truncated, 
may facilitate their spreading and tissue propagation. It would be interesting to compare the 







Following this accurate characterization of PrP A53T αS Tg mice from a GI perspective and with 
a specific focus at the prodromal phase, our research moved toward a disease modifying 
approach. The therapeutic intervention was designed to be applied during the favorable time 
window we had identified, when Tg mice start showing an altered but not yet consistent transit 
time and in absence of any other sign at the central level. We used an ASO, administred to Tg 
mice at 10 weeks of age, for a continuous period of 7 days. As previously explained, ASOs are 
small, single-stranded sequences of nucleic acids able to bind to a complementary target mRNA, 
this binding causes the recruitment of RNase H enzyme (in our specific case) that in turn degrades 
the target RNA, thus preventing its translation into protein. This approach has been proven 
successful in preclinical trials for a variety of neurodegenerative diseases, characterized by the 
accumulation of specific proteins, such as αS in PD (DeVos and Miller, 2013). Several empiric 
data revealed a widespread distribution through brain and spinal cord following intraventricular or 
intrathecal administration followed by positive phenotypic effects, in mice (Devos et al., 2013; 
Lagier-tourenne et al., 2013), rats (Smith et al., 2006) and non human primates (Kordasiewicz et 
al., 2012; Rigo et al., 2014). Thanks to these results, ASOs made it to clinical trials in which 
intrathecal delivery led to positive outcomes in terms of safety and tolerability for patients 
affected by amyotrophic lateral sclerosis (Miller et al., 2013) and spinal muscular atrophy 
(Chiriboga et al., 2016). Very recently two ASOs finally received FDA approval, Nusinersen for 
spinal muscular atrophy (Aartsma-Rus, 2017) and Eteplirsen for Duchenne muscolar distorphy 
(Lim et al., 2017), representing the first cases of disease modifying therapy for neurodegenerative 
diseases. Other clinical trials are ongoing for Huntington’s disease and spinocerebellar ataxias 
(Scoles and Pulst, 2018). It is important to underline that the therapeutic use of ASOs, especially 
for neurodegenerative diseases, is often based on the target of the whole protein level and not 
exclusively its toxic form. The overload of certain proteins plays a pivotal role for these 
pathologies both in their native and toxic forms (strictly interdependent), thus reducing the total 
amount of a protein can re-establish its altered homeostasis in a broader manner. 
Although CNS-directed administration routes have been well tolerated so far, they remain quite 
invasive and for this reason researchers are pointing toward novel peripheral delivery methods for 
ASOs still utimately aimed at the nervous system, such as subcutaneous, oral and intranasal routes 
(Schoch and Miller, 2017). A number of studies carried out in mice showed that the peripheral 
administration (intraperitoneal or tail vein injection) of ASOs resulted in a positive effect at the 
neuronal level, in the PNS (Bogdanik et al., 2015) and in the CNS (Erickson et al., 2012; Farr et 
al., 2014), meaning that the ASOs were able to cross both the blood nerve barrier (BNB) and the 
blood brain barrier (BBB). Another study was able to individuate a saturable system (termed 
oligonucleotide transport system-1) which facilitates the transport of ASOs across the BBB in 
mice, following intravenous administration (Banks et al., 2001). The BNB, despite some 
differences in composition compared to the BBB, plays a similar role and can be equally effective 
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in excluding specific molecules from the neural parenchyma in vivo (Choi and Kim, 2008; Kanda, 
2013), thus it is possible that they share also similar transport systems. Additionally, it is 
important to take into account that neurodegenerative diseases are often characterized by 
neuroinflammation and disruption of the vascular barriers (Tomkins et al., 2007; Winkler et al., 
2014; Sweeney et al., 2018), including PD (Kortekaas et al., 2005; Shi et al., 2014). Such 
alterations might further facilitate the ASO crossing of neural barriers, in animal models and in 
human subjects. In order to extert its effects on the target mRNA an ASO has to overcome 
membrane barriers outside and inside the cell. Although the details of these mechanisms may 
differ across cell types and still require further investigations, it has been recently explained how 
the process of ASOs entering into cells requires the inclusion in lysosomal or endosomal 




Fig.4.2 Schematic representation of BNB and BBB in radial section. Although the BNB (left) differs 
from the BBB (right) in some components, they both exert a similar function in controlling the passage of 
molecules aimed to protect the nerves and the brain, respectively. In both cases, endothelial cells (orange) 
are connected by tight junctions (red rectangles) and embedded in a single basement membrane (pink) with 
surrounding pericytes (blue). Only in the BBB, a second glial membrane (light green) wraps the just 
mentioned structures, still leaving a so called perivascular space, and an astrocytic endfoot layer (dark 








All this considered, we decided to perform rectal and intraperitoneal administration, the latter 
exploiting a continous drug diffusion through osmotic pumps, in order to target the colonic ENS 
with an ASO against αS, chosen among others following an in vitro evaluation. Since αS 
pathology in these mice is found in both submucosal and myenteric plexi, we speculated that we 
might have the chance to reach both by means of two routes. As expected, with both delivery 
methods the ASO reached neuronal and non neuronal cell types at the level of the colon, 6 h after 
rectal administration or 3 days after osmotic pump implant, indicating that it was absorbed by the 
tissue already at early time points. After this confirmation, we performed a 1 week ASO treatment 
in 10 weeks old Tgs, to evaluate whether local inhibition of αS protein expression could improve 
the deficit in GI transit. Very surprisingly, after only 7 days of treatment, Tg mice which received 
the ASO displayed a significant reduction in their WGTT compared to the values before starting 
the treatment and to the PBS control group, for both administration routes. Concomitant with the 
improvement in constipation, ASO treatment induced a reduction, although not significant, in the 
total level of αS in the distal colon but not in the proximal colon, for both delivery methods. The 
lack of inhibitory effect in the initial tract of the large intestine was not surprising, since the 
osmotic pump was positioned close to the distal colon and the rectal administration was not such 
invasive to reach consistently the upper tract of the colon. Nevertheless, since the distal colon in 
this mouse model is more affected in terms of αS deposition compared to the proximal segment, 
targeting this area appeared to be sufficient to obtain, directly or indirectly, an improvement of 
WGTT. The results obtained highlight the necessity to repeat the experiment on a larger sized 
group of mice. Nonetheless, our data positively support the correlation between GI behavior and 
αS levels in this PD mouse model. Although we cannot rule out the possibility of a CNS 
involvement since we have not measured the ASO levels in blood or cerebrospinal fluid, these 
data still indicate that reducing the total level of αS locally is associated with an improvement of 
GI transit time. 
Thus, our study supports the hypothesis that lowering the total level of aggregation-prone proteins 
can be a successful disease modifying therapy against neurodegenerative diseases. We strongly 
believe that ASO therapy will make a difference for such disorders and that a peripheral approach 









Conclusions and future directions 
 
The overexpression of αS in the ENS of the PrP human A53T αS Tg mouse model line G2-3 
causes constipation and colon contractile deficits. This enteric dysfunction represents an early 
symptom of α-synucleinopathy that occurs at least 6 months before motor symptoms and 
neurodegeneration in the CNS. From a biochemical point of view, such pathology is evident in 
the colon of these mice, where αS accumulates abnormally in different neuronal types of the ENS, 
in a time dependent manner. Thanks to the net spatio-temporal separation of the two αS-driven 
pathologies first in the colon and then in the CNS, this mouse line is a unique model to investigate 
the gut-brain connection in PD progression and to study GI dysfunction in prodromal PD. 
Promising results arised from targeting the colon through a brief ASO treatment, in terms of GI 
phenotype recovery and disease modifying therapy. Additional experiments are required in order 
to verify whether the putative positive effects of a longer ASO treatment may slow or halt the 
enteric α-synucleinopathy from reaching the brain. In parallel, ongoing research is investigating 
the state of inflammation and permeability of the colon in A53T αS Tg presymptomatic mice, in 
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